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 Clinical trials for drugs and vaccines often suffer from the use of culture or animal 
models that do not accurately recreate the microenvironment of human tissues, including 
the lymph nodes. Furthermore, insufficient immune function resulting from genetic 
deficits, cancer or auto-immune disease, and the loss of lymph nodes due to surgical 
resection or radiation therapy may benefit from the implantation of therapeutic immune 
cells. These needs could be served through the development of a biocompatible, 
vascularized, 3D hydrogel scaffold that supports leukocytes and recreates lymph node 
function by providing a biomimetic microenvironment. While other lymph node models 
exist, their complexity and function are limited in that they incorporate few of the 
bioactive molecules from the lymph node microenvironment and do not contain 
vasculature. 
 Preliminary viability studies were performed to determine the optimal choice of 
hydrogel type and density for the 3D culture of peripheral blood mononuclear cells 
(PBMCs). Fibrin hydrogels were found to better maintain PBMC viability over three 
days compared to gelatin methacrylate hydrogels. The inclusion of ECM from 
decellularized porcine lymph nodes into fibrin hydrogels was met with technical 
challenges with regard to solubilization and peripheral blood cell (PBC) viability 
assessment, indicating that additional steps or different approaches were required. 
However, successful decellularization was demonstrated by the sufficient removal of 
DNA content as determined by DNA quantification and histological staining. Cytokine 
and growth factor analysis showed significant depletion of many of the analytes but 
retention of IFNα2, IL-3, IL-9, IL-13, IL-17A, and VEGF. To construct a perfusable 
model, pin molds were used to create channels that would undergo eventual 
endothelialization and angiogenesis. Few of these channels maintained structural 
integrity. While continued experimentation is required to implement all of the features 
desired for the construction of a biomimetic and functional human lymph node model, 
these results indicate that it is feasible to improve upon previous designs by incorporating 
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The purpose of the lymphoid system is to defend the body from pathogens while 
maintaining tolerance of the body’s own tissues and avoiding adverse reactions to non-
pathogenic external sources of antigens (i.e., commensal bacteria, food, etc.). The 
requisite functions for the achievement of this purpose are divided between different 
subsets of immune organs. The primary lymphoid organs, namely the thymus and bone 
marrow, are the sites for production and differentiation of hematopoietic progenitors into 
lymphoid and myeloid cells which provide the adaptive and innate branches of the 
immune response. They also provide an environment conducive to the selection of the 
lymphocytes, which are functional yet do not display pathogenic autoreactivity. The 
secondary lymphoid organ subsystem is comprised of the spleen, lymph nodes, tonsils, 
Peyer’s patches, adenoids, and other lymphoid formations which are found in a variety of 
tissues and referred to as the mucosa-associated lymphoid tissues1. These organs survey 
the body (primarily through the lymphatics) for antigens and are responsible for 
mounting an adaptive immune response by selectively activating B and T cells whose 
receptors are specific to the threat. Alternate forms of the antigen-specific receptors on B 
cells are secreted as antibodies. Tertiary lymphoid organs form in tissues experiencing 
chronic inflammation and perform many of the same functions as secondary lymphoid 
organs. Finally, the lymphatic vasculature, although not placed in any of these three 
categories, plays a vital role in the transportation of immune cells and pathogens. In 
addition, the lymphatic endothelial cells of the vasculature support secondary lymphoid 
organs by enabling immune cell chemotaxis and antigen presentation2. Within the 
lymphatic organs, lymphocytes are supported by a variety of stromal cells which provide 
them with signals needed for survival, growth, development, and migration.  
 
1.1 Lymph node structure and function 
The peripheral lymphatic system includes the spleen and lymph nodes as well as 





are distributed throughout the body3. The purpose of these organs and tissues is to 
enhance immune surveillance by filtering extracellular fluids, providing an environment 
for effective antigen capture and presentation, and facilitating adaptive immune 
responses3. Extracellular fluid called lymph drains from tissue and flows into the lymph 
nodes via afferent lymphatic vessels. It brings antigens that are produced by infection or 
malignancy (see Fig. 1.1)3. Lymph flow also transports inflammatory mediators generated 
by the innate immune response at the site of infection, such as interleukin-1β (IL-1β) and 
tumor necrosis factor α (TNFα)4,5. Furthermore, antigen-bearing dendritic cells (DCs) are 
carried by the lymphatic vasculature and actively recruited to the lymph nodes by 
chemokine gradients5. The primary chemokines which mediate the migration from the 
lymphatic vasculature to the lymph nodes are C-C motif chemokine ligand 21 (CCL21) 
and C-C motif chemokine ligand 19 (CCL19) (see Fig 1.1)6. CCL21 is produced by the 
endothelial cells of the high endothelial venules (HEVs) and both chemokines are 
secreted by fibroblastic reticular cells (FRCs)6,7. These molecules also promote the entry 
of naive T cells into the lymph nodes, while B cell integrin activation and subsequent 
migration are also dependent on the chemokines C-X-C motif chemokine ligand 12 






Figure 1.1 The lymph nodes facilitate interactions between stromal cells and lymphocytes which allow 
activation and the progression of the adaptive immune response. Adapted from Nosenko et al.9. 
Reproduction is permitted under the terms of the Creative Commons Attribution 4.0 International license. 
 
DCs in the lymph nodes can either be resident cells or migratory cells which are 
recruited from the peripheral tissues after their activation in response to inflammation7. 
DC motility is promoted by the upregulation of chemokine receptor C-C chemokine 
receptor 7 (CCR7) and lectin CLEC-2, upon activation7. Resident DCs can acquire 
soluble antigens which flow into the lymph node and some can even process viruses and 
bacteria which arrive by the same conduits and end up in the subcapsular sinus (SCS)7. 
Furthermore, DC signaling can promote the expansion of the lymph node’s vascular and 
stromal networks in response to infection in order to remodel and enlarge the organ to 
improve capacity and function7. 
Although DCs are the primary antigen presenting cells (APCs) in the lymph node, 





node macrophages are distinct from those that arise from monocytes and are present as a 
resident population10. They fall into a number of distinct subtypes which are localized to 
the SCS, medullary sinus, medullary cords, or interfollicular regions10,11. Furthermore, 
lymph node macrophages are susceptible to viral infection, which may allow them to 
enable viral replication for the purpose of creating enough viral antigen to promote an 
adaptive immune response10. 
 B and T lymphocytes are present in designated, separate areas in the lymph 
node3. The lymph node lobule, its basic functional unit, is separated from the outer, 
fibrous capsule of the lymph node by the SCS (see Fig. 3.8 panel a, solid arrow), into 
which lymph flows from afferent vessels (see Fig. 3.8 panel b, dashed arrow)4. Further 
subdomains contain specific populations of cells and enable their function. The 
superficial cortex contains the follicles and interfollicular cortex4. B cells are primarily 
found in the follicles and this is where germinal center (GC) formation and activity occur 
(see Fig. 3.8 panel a, solid circle)4. T cells interact with DCs in the interfollicular cortex 
and the deeper paracortex (see Fig. 3.8 panel a, dashed circle). The latter region is where 
they proliferate after activation4. The medulla contains the medullary sinuses and 
medullary cords and contains activated B cells, or plasma cells, which produce 
antibodies4,12. Medullary sinuses converge on the efferent vessel through which 
lymphocytes can exit the lymph node4. T cell localization to their zones is maintained by 
the action of chemokines CCL19 and CCL21. B cells are similarly attracted to the 
follicles by CXCL133. The colocalization of DCs and T cells enables high rates of 
antigen presentation to facilitate the adaptive immune response3. 
Upon activation, T cells migrate to the edges of their zones to encounter B cells 
and provide helper signals to activate them3. This is performed primarily through the cell-
surface expression of CD40L and secretion of interleukin 21 (IL-21), which promote B 
cell survival, proliferation, and differentiation. Activated lymphocytes proliferate and 
differentiate in the lymph node and leave via the efferent vessels to perform their effector 
functions. The exit of T cells from the lymph node through the cortical sinuses, to the 





sphingosine 1-phosphate (S1P). Activated T cells express fewer of the receptors for this 
lipid molecule in order to remain within the lymph node until they are ready to fulfill 
their effector function3. Aside from T helper cells, there are a variety of effector T cells. 
Cytotoxic CD8+ T cells promote viral immunity by killing virally infected cells, while 
TH1, TH2, and TH17 cells mediate immunity against intracellular pathogens, parasites, 
and bacteria, respectively3. Activated B cells can become plasma cells which produce 
antibodies that enhance immunity by neutralizing pathogens through a variety of means3. 
A subset of activated B cells become memory B cells which are maintained over a longer 
period of time to provide a faster adaptive immune response against future infection by 
the same or similar pathogens3. 
B cell zones are home to the GC reaction, a key process which results in B cell 
antibody class switching and affinity maturation12. GCs are temporary structures that 
form in response to B cell activation from T cell-dependent signaling12. A subset of these 
B cells undergoes phenotypic changes and enter the center of the follicle where they 
proliferate rapidly and experience somatic hypermutation, a B cell receptor (BCR)-
changing process which results in a population of B cells that can produce higher-affinity 
antibodies12. Class switching diversifies the repertoire of antibodies that can be produced 
by changing the immunoglobulin (Ig) gene to provide isotypes with specialized function3. 
Stromal cells in the lymph nodes provide support to leukocytes by forming 
structures and secreting soluble chemical signals11. FRCs are present in the paracortex 
and, as previously mentioned, secrete CCL19 and CCL2111. FRCs also form the reticular 
network in conjunction with reticular fibers, bundles of basement membrane-covered 
collagen, which they produce4. Lymphocytes migrate along this network by binding to 
FRC-expressed adhesion ligands and are simultaneously exposed to the conduits within 
the network which allow the transport of antigen and inflammatory signals4. Follicular 
dendritic cells (FDCs) are present in the follicles alongside B cells and produce both 
CXCL13 and B-cell activating factor (BAFF), which promote B cell localization and 
survival, respectively3,11. Marginal reticular cells (MRCs), found in the subcapsular sinus, 





In addition to stromal cells, lymphatic endothelial cells (LECs) play an important 
role in delivering cells, cytokines, and antigen to the lymph nodes. They also directly 
enable transmigration of leukocytes across the vessel wall by expressing hyaluronic acid 
receptor LYVE-1, adhesion molecules ICAM-1 and VCAM-1, and chemokine CCL2114. 
Furthermore, LECs produce interleukin 7 (IL-7) which promotes lymphocyte expansion 
during an immune response15. Finally, LECs play a role in regulating T cell tolerance by 
acquiring or delivering antigens to or from DCs for presentation to CD4+ T helper cells 
and expressing peripheral antigens for presentation to CD8+ cytotoxic T cells15. LECs 
undergo proliferation and migration primarily in response to lymphangiogenic growth 
factor vascular endothelial growth factor C (VEGF-C), which can be provided by a 
variety of cells including macrophages and B cells15,16. 
Lymphocytes interact with ECM proteins in the lymph nodes that can impact their 
migration, survival, and proliferation17. Many of these proteins are found within the 
basement membranes of the lymph node vasculature and the reticular network. The latter 
contains collagens I, III, and IV which provide structural strength and adhesion ligands18. 
Collagen IV is found in basement membranes and reticular fibers alongside laminins, 
trimeric proteins which contain adhesion ligands and are named after their combination 
of α, β, and γ subunits, in that order. Laminins 332, 411, and 511 are found in the 
reticular fibers and promote lymphocyte migration17. Moreover, laminin 511 promotes T 
cell proliferation17. Laminins 411 and 511 are found in the basement membranes of the 
lymph node vasculature and it has been shown that the ratio of their abundance may have 
an impact on the strength of immune responses19,20. Laminins in the lymph nodes are 
thought to primarily be secreted by FRCs but some studies have indicated that 
lymphocytes may also produce laminins 411 and 51119. Fibronectin is an adhesion 
ligand-containing protein that is also associated with the reticular network in lymph 






1.2 Tissue engineering 
The design of biomimetic constructs or models, grounded in an understanding of 
biology and engineering principles, has made significant contributions to the field of 
regenerative medicine and resulted in a supply of commercially available products that 
are used to develop approaches to replace injured or dysfunctional tissues. This endeavor, 
known as tissue engineering, makes use of cells, scaffolds, and a variety of chemical or 
physical signals to replicate the structure and function of natural tissues (see Fig. 1.2). 
For the purposes of immune tolerance, it is often most efficacious to use autologous cells 
from the intended recipient of a tissue engineered construct22. These cells may be taken 
from a patient to be expanded and seeded in scaffold ex vivo or they may simply be 
recruited to a site of implantation of such a scaffold to be incorporated into a design in 
vivo. Stem cells are another useful resource since they are self-renewing and capable of 
differentiation. The term scaffold refers to a variety of three-dimensional structures, 
which can be used to contain and provide signals to cells. These may be derived from 
natural materials or from synthetic sources and generally have pores or channels which 
allow the movement and interaction of one or more cell types within the construct. It is 
imperative that these materials not be cytotoxic and that, if they are intended to be 
implanted, display full biocompatibility with the recipient animal model or human 
patient.  
Signals which are used in tissue engineered designs may include chemical signals 
such as growth factors, cell adhesion peptides, chemokines, and other relevant molecules 
that promote viability, proliferation, migration, or specific functions of a target cell 
population. Physical signals may be provided by the material used for scaffolding, as is 
the case for factors such as stiffness or surface topography. External physical signals such 
as fluid flow, tensile or compressive loading, and even electrical stimulation can play an 







Figure 1.2 Tissue engineering design often utilizes a combination of scaffold materials, cell types, and 
environmental signals to replicate natural function and achieve desired outcomes. Reproduction of the 
artwork: “Ligand”, “Receptor”, “Lymphocyte”, and “Collagen” by Servier Medical Art at 
https://smart.servier.com/ is permitted under the terms of the Creative Commons Attribution 3.0 Unported 
license. 
 
 The design of a tissue engineered construct generally falls into one of a set of 
distinct approaches. One standard approach involves the seeding of cells into a porous 
scaffold. Such a design may be constructed by the casting or bioprinting of a polymeric 
material or hydrogel. Hydrogels are comprised of hydrophilic, crosslinked polymers 
which form a 3D network that absorb and swell with water23. These characteristics 
provide a porous, aqueous environment that allows the diffusion of nutrients, oxygen and 
various chemical signals23. They can often be formulated or modified to achieve desirable 
mechanical properties and incorporate adhesion ligands or other bioactive molecules, 
allowing them to mimic the microenvironment of various tissues23. One major concern 
regarding the choice of materials with which to assemble an appropriate hydrogel is 
cytocompatibility, as the cells of therapeutic interest need to maintain high viability and 
function23. Another is the potential for vascularization, a process that enables better 
transport of relevant cells and signals throughout the scaffold. Vascularization of tissue 





popular choice of hydrogel is that which is made from gelatin methacrylate (GelMA). 
GelMA is a combination of the natural, polymeric material, gelatin, and methacrylic 
anhydride24. It can be crosslinked with the aid of a photoinitiator and ultraviolet (UV) 
light source. GelMA contains cell-binding RGD peptide motifs. It is mechanically and 
chemically tunable, biodegradable (due to sites recognizable by matrix 
metalloproteinases), and bioprintable24. Fibrin is another widely used hydrogel. It is 
formed by the cleaving and subsequent polymerization of a natural monomer, fibrinogen, 
which occurs due to the action of thrombin25. In the body, fibrin plays an important role 
in blood clotting and wound healing. It has been used for its angiogenic potential and, as 
a natural scaffold, is highly biocompatible25. 
Hydrogels and other 3D culture scaffolds can be assembled in a variety of ways 
and with or without additional supporting structures. Bioprinting provides a means of 
creating a complex spatial organization that may not be possible with simpler methods 
but requires the use of materials whose properties allow them to be effectively printed26. 
When stem cells are placed in 3D clusters that self-organize and differentiate into 
requisite somatic cell types, it is known as organoid formation27. This approach is often 
supported by placement of the cells within a scaffold material, but it is also possible for 
these cells to secrete their own ECM. To provide cells within a tissue engineered 
construct that is maintained in vitro with nutrients and waste removal, scaffolds are often 
placed within a perfused housing known as a bioreactor. Bioreactors can also be used to 
provide chemical or physical signals with or without temporal variation. Alternatively, a 
construct can be implanted into an animal model for in vivo maturation or designed to 
simply exert its effect directly upon implantation within a patient, as is the case with 
many injectable scaffold approaches. Advances in microfluidic technology have led to its 
combination with 3D cell culture to create organ-on-a-chip models. An advantage of this 
approach is the high degree of control over architecture and perfusion which it imparts28.  
Another technology, which permits use of the body’s own structural design, is 
decellularization: removal of cellular content from an organ or tissue leaving behind the 





acids/bases, enzymes, or a combination of these methods29. Surfactants disrupt the lipid 
bilayer of cells in the sample to lyse them and remove their nuclear material29. Some 
commonly used surfactants include Triton X-100, sodium dodecyl sulfate (SDS), sodium 
deoxycholate, and 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate 
(CHAPS)29. SDS is highly effective at removing nuclear material but tends to damage the 
ECM of the tissue29. CHAPS, sodium deoxycholate, and Triton X-100 can be used to 
preserve the ECM to a greater degree29, 30. However, CHAPS and sodium deoxycholate 
tend to be less effective at total removal of nuclear material and may need to be used in 
multiple cycles or with additional agents29. Acids and bases disrupt the membrane 
through solubilization29. These have been found to be damaging to certain components of 
the ECM31. Finally, enzymatic agents such as trypsin-ethylenediaminetetraacetic acid 
(EDTA), pepsin, and DNase I can be used to supplement these approaches. Trypsin-
EDTA and pepsin break bonds between the ECM and cell, while DNase I can be used to 
degrade DNA segments29,31. Trypsin-EDTA and pepsin need to be used with care, as 
overexposure to the tissue may break down the ECM31. 
 In addition to consideration of the scaffold type and method used, the material 
itself is an important factor. Many synthetic materials are easily and consistently 
producible and can be modified with natural peptides or other bioactive molecules to 
impart biological function32. These modifications can often be forgone if a naturally 
derived material is chosen but these are generally harder to manipulate and process, and 
can be more vulnerable to batch variability32,33. 
 
1.3 Objectives of lymphoid tissue engineering 
Lymphatic bioengineering involves the use of cells and biological factors in an 
appropriate medium or scaffold to reconstruct or mimic the function of some part of the 
lymphoid organ system. This endeavor has the potential to provide the medical sector 
with a variety of services. For example, it could better establish the efficacy and safety of 





the resultant, potentially immunotoxic, response. The advent of highly biomimetic, three-
dimensional engineered models of each organ of the immune system could provide the 
industry with a reliable, reproducible, cost-effective, and ethical alternative to the pre-
clinical trials which are performed on animal models and whose results often translate 
poorly to the clinical phase28,34,35. Some other, experimentally related concerns with the 
use of animal models include the presence of fundamental differences in the immune 
systems of different species and the inability to fully measure or control the complex 
cellular interactions in a test subject27,28. Additionally, in vitro models provide a 
multitude of experimental benefits including the ability to manipulate signaling 
pathways, engineer tissue niches, and introduce epigenetic or genomic alterations to cell 
lines36. Of these, the ability to recreate the appropriate, 3-dimensional tissue niche in 
terms of ECM components, chemical gradients, scaffold stiffness, and other mechanical 
gradients is especially vital for immune cell function, giving a bioengineered tissue 
model an advantage over oversimplified, 2-dimensional culture systems28,36. 
Furthermore, in vitro models provide an improved system for imaging or performing 
molecular analyses at multiple timepoints in an experiment, thereby allowing observation 
of temporal dynamics27,37. Finally, bioengineered models have the potential to 
encapsulate individual specificity within therapeutic screening tests by isolating, 
expanding, and seeding the patient’s own cells in the scaffold or construct. This could 
serve to capture the traits of their specific disease by using affected cell populations, 
avoid adverse immune responses to allogeneic cells, and characterize their personalized 
reaction to a drug or immunotherapy28,35,38. 
Alongside providing in vitro systems for drug and immunotherapy screening, 
bioengineered lymphatic tissue models can provide a means of studying the dynamics of 
auto-immune disease and cancer within an organ-specific microenvironment9,34. This 
could elucidate the evolution of these pathologies and give insight on potential 
immunotherapeutic approaches based on the interactions of diseased cells with 





Another beneficial outcome of the progression of lymphatic tissue engineering 
would be the implantation of secondary lymphoid organ constructs to replace or bolster 
inadequate natural immune function. Such an approach could be used as a vehicle for 
immunotherapy by implanting immune cells in a physiologically and pathologically 
relevant location. These cells could be pre-primed against an antigen particular to the 
infectious disease vector or to the cancer type of interest. They can also be provided with 
the appropriate microenvironment by the scaffold they are seeded in, allowing in vivo 
expansion and improved viability. Furthermore, this tactic could be used to combat 
pathological inflammation and auto-immune disease by providing a population of 
regulatory immune cells to control these adverse immune responses38. Additionally, the 
negative effects of genetic disorders involving an inhibition of lymphatic organ 
development or lack of function such as DiGeorge syndrome or Fanconi anemia could be 
circumvented by implantation of an appropriate lymphatic tissue construct to restore 
function. As a final application, the implantation of a tissue-engineered secondary 
lymphoid organ construct (alongside engineered lymphatic vasculature, as needed) could 
be used as a direct tissue replacement to treat inherited or acquired lymphedema, the 
accumulation of interstitial fluid resulting from insufficient lymphatic drainage. Acquired 
lymphedema is often a result of radiation therapy or tumor removal39. Another benefit of 
such a replacement would be the restoration of immune surveillance provided by the lost 
lymphatic organs and vasculature. 
 
1.4 Current strategies for tissue engineering lymph nodes 
Many of the lymph node tissue-engineering studies of the last two decades have 
been focused on either the production of a GC reaction (using only B cells) or on the 
formation of more efficient immunological synapses (T cells and APCs) in 3D. Of the 
former, studies by Purwada et al. show promising results. In the first of these 
publications, a gelatin and silicate nanoparticle hydrogel was used to incubate B cells in 
the presence of a transgenic stromal cell line and exogenous IL-440. The stromal cells in 





(TFH) cells and FDCs found naturally in the lymph node. The latter study replaced the 
modified gelatin matrix with a polyethylene glycol (PEG)-maleimide scaffold conjugated 
with adhesion peptides and was able to achieve GC-like B cell phenotypes, antibody class 
switching, and the production of antigen-specific B cells41.  
With regard to those studies focused on the formation of immunological synapses 
and T cell activation, microfluidic devices provide a highly controllable format with 
which to study specific behaviors, as demonstrated by Rosa et al. in a study that looked at 
T cell and DC interactions under controlled flow conditions42. The use of artificial APCs 
for the activation of T cells in 3D culture conditions has been recently investigated by 
research groups out of Barcelona and Harvard and found to have an advantage over 
traditional 2D culture approaches43,44. The study by Cheung et al. found success in the 
complementary use of soluble mitogenic signals and liposome membrane-bound T cell 
receptor (TCR) stimulation ligands co-delivered by matrix-forming silica microrods to 
achieve rapid expansion of T cells44. Finally, injectable gels have proven their use in the 
delivery and expansion of T cells in vivo. This was accomplished using an alginate gel 
functionalized with GFOGER peptide, and through a polyisocyanopeptide hydrogel 
functionalized with GRGDS45,46. This approach can be applied to the immunotherapeutic 
treatment of cancer by delivering and expanding T cells that can recognize tumor-specific 
antigens at the location of a tumor or tumor resection site45. These studies included an 
integrin-binding peptide to enable cell migration and egress from the gel into the site of 
interest45,46. 
Of the studies that involve both T and B lymphocytes, long term research by 
Giese et al. has resulted in a bioreactor with RGD-Dextran gel discs that is able to 
support a lymphocytic immune response to protein aggregates, and maintain separated T 
and B cell zones, mimicking secondary lymphoid organ structure47. While this series of 
publications focused on in vitro functionality, other studies implemented in vivo 
recruitment of immune cells to seed implanted collagen sponges supported by thymus-
derived stromal cells48,49. These efforts resulted in the induction of distinct B and T cell 





immune response upon further stimulation. There have also been recent attempts to 
utilize decellularized lymph nodes as a scaffold for the in vivo production of potentially 
therapeutic cell populations. One example is the work of Lin et al. demonstrating the use 
of this approach to produce anti-tumor DCs in a biologically relevant 
microenvironment50.  
For a comprehensive review of lymphoid tissue engineering, please see appendix 
section A.3. This review has been submitted to the Journal of Immunology and 
Regenerative Medicine and is currently in revision. 
For the purposes of creating a lymph node model construct that is highly 
biomimetic with applicability in vitro as well as in vivo, it is important to choose an 
approach which allows an ease of manipulation and control with clinically and 
physiologically relevant size and complexity. Hydrogels are a prime candidate for this, as 
they can be relatively easily produced, have the potential to be utilized in rapid 
manufacturing practices such as 3D bioprinting, and contain base materials which can be 
tuned, modified, and supplemented to implement target characteristics. These 
characteristics include parameters such as stiffness, degradation time, density and 
distribution of cells and chemical signals, and size. However, since the complexity of 
ECM composition and microstructure can be very difficult to replicate, it may prove 
useful to implement decellularized ECM from native tissue. An additional key foresight 
lies in the choice of method for supplying the construct with a continual source of 
nutrients and means of waste removal. Designs lacking this feature may be limited in 
their functional duration. Bioreactors fit this description but do not guarantee complete 
diffusion of nutrients and waste products through the entirety of the construct. A 
sufficient degree of vascularization might accomplish this goal and add important cell-
cell interactions through the incorporation of endothelial cells. A vascularized hydrogel 
scaffold with the appropriate cell populations, chemical and ECM supplementation, and 
means of perfusion could meet the needs for a versatile and effective tissue engineered 







2.1 PBMC/PBC isolation and hydrogel seeding 
 PBMCs were obtained [with natural killer (NK) cells removed] from the Dr. 
Jeffrey Miller lab (University of Minnesota, Minneapolis). The cells were attached to 
microbeads when received. These cells were incubated overnight at 37°C and 5% CO2 in 
a 150 cm2 flask (Corning, Corning, NY) with X-VIVOTM 15 cell medium (Lonza, Basel, 
Switzerland) to allow them to detach from the beads. The next day, the cells were used in 
3D hydrogel culture assays. Discarded normal donor peripheral blood cells (PBCs) 
[Angela Panoskaltsis-Mortari] were provided by the Cytokine Reference Laboratory 
(University of Minnesota, Minneapolis). The layer containing hematopoietic cells was 
drawn from the tubes and placed in an ammonium chloride RBC (red blood cell) lysis 
solution (07850, Stemcell Technologies, Vancouver, Canada) at a 1:9 ratio. Cells were 
mixed by tube inversion and placed on ice for 10 minutes to lyse RBCs. PBCs were 
washed in AIM V medium (ThermoFisher Scientific, Waltham, MA) and PBMCs/PBCs 
were counted using a hemocytometer (Hausser Scientific, Horsham, PA) and Nikon 
Labophot microscope (Nikon, Tokyo, Japan). 
 GelMA (gelatin methacrylate) solutions were prepared by mixing 10%, 16%, 
20%, or 24% w/v stock solutions of GelMA, which was provided by the University of 
Minnesota 3D Bioprinting Facility, with 1% w/v lithium phenyl-2,4,6-
trimethylbenzoylphosphinate (LAP) (UV crosslinking agent, Allevi, Philadelphia, PA) in 
culture medium. All solutions containing LAP were prepared in the dark and wrapped in 
aluminum foil until they were combined with cell suspensions and crosslinked. These 
solutions were diluted by a factor of two when mixed with an equal volume of a cell 
suspension. Fibrinogen solutions were prepared by mixing human plasma fibrinogen 
(341576, MilliporeSigma, Burlington, MA) at concentrations of 10, 20 or 40 mg/mL in 
the culture medium. This solution was combined with cell suspensions of equal volume 
and a 10 U/mL stock solution of human plasma thrombin (605190, MilliporeSigma). 
Cells were seeded at 250x103/mL, 10x106/mL, or 20x106/mL in well-mixed suspensions. 





and laminin 511 (BioLamina AB) were added to the fibrinogen solution at a final 
concentration of 10 μg/mL. In cases where processed porcine lymph node ECM was 
included, fibrinogen was added to AIM-V medium containing 10 mg/mL of the ECM. 
 Fibrinogen solutions were mixed with cell suspensions in a 24 or 48 well plate 
(CELLTREAT, Pepperell, MA) in sterile conditions. Thrombin, at a 10 U/mL stock 
concentration, was thawed and kept on ice then added to the wells to reach a final 
concentration of 1 U/mL. Each well’s contents were mixed thoroughly with a pipette and 
then the plate was allowed to incubate for 30 minutes at 37°C and 5% CO2 to allow the 
fibrinogen to crosslink and form a fibrin hydrogel. GelMA stock solutions were mixed 
thoroughly with cell suspensions in a 48 well plate (CELLTREAT) and then crosslinked 
for 70 seconds, at a distance of 13 cm from a 405 nm light source provided by an 
INKREDIBLE 3D bioprinter (Cellink). After crosslinking, hydrogels of either type were 
covered in 400 μL of culture medium (see Fig. 2.1). 
 
Figure 2.1 220 μl fibrin gels containing PBCs. The gels in the left half of the plate had already been imaged 
and were not covered with culture medium at the time this picture was taken. The gels in the right half of 







Figure 2.2 Close-up of the hydrogels in wells D3 and D4 shown in Figure 2.1. 
 
 
2.2 PBMC/PBC 3D culture and imaging 
 Cell-containing gels were incubated at 37°C and 5% CO2 for either 24 or 72 
hours. In later experiments, the culture medium covering the gels was replaced every day 
for each of the 72 hour trials. At the end of the incubation period, the culture medium 
covering the gels was aspirated and replaced with 200 μL of LIVE/DEAD® Viability 
Assay reagent (L3224, Invitrogen, Carlsbad, CA) containing calcein acetoxymethyl (AM) 
and ethidium homodimer-1. The reagent was incubated with the hydrogels for 1 hour. At 
that point, the remaining reagent was aspirated from the surface of the gels. An Evos FL 
Auto 2 microscope (Invitrogen) was used to image gels in green and red fluorescence 
channels to determine the number of live and dead cells, respectively. Z-stacks were 
compiled from images that began at the lowest focal plane that contained in-focus cells 
and ended at the highest focal plane that contained in-focus cells. This depth ranged from 
0.2 to 1 mm, depending on the gel. Z-stacks were taken in the middle of each gel to avoid 
edge effects and provide sampling consistency.  
 
2.3 Quantification of viability 
 Upon obtaining Live/Dead (L/D) fluorescent images of PBMC/PBCs, grid 





counting. A tally of live and dead cells was kept for every other row in the grid in each 
sample image. Cells falling on the right and upper boundaries of a given grid square were 
included in its count, and those on the left and lower boundaries were not, so as to avoid 
double-counting. Row totals were added together to obtain the final count for each image. 
Viability was calculated as the percentage of live cells within a given number of total 
cells. For each experimental condition where multiple trials were performed, mean 
viability and standard error were calculated. 
 
2.4 Obtaining lymph nodes 
 Porcine mesenteric lymph nodes were obtained from waste carcasses from the 
Visible Heart Laboratory (University of Minnesota, Minneapolis, MN). Fatty connective 
tissue was removed from the tissue samples using tweezers and dissecting scissors. 
Lymph nodes were flash frozen whole for use in histology or further dissected into ~2-
5mm pieces for decellularization (see Fig. 2.2). Additional samples were likewise 
dissected into smaller pieces and used in dsDNA or soluble protein content analysis. A 
human lymph node which had come with lungs that previously been purchased from the 
International Institute of the Advancement of Medicine (Edison, NJ) and frozen whole in 
O.C.T. was used to create sections for positive IHC controls.  
 
2.5 Decellularization and digestion of porcine lymph nodes 
 Decellularization of porcine lymph nodes was performed using studies by 
Galliger et al. for tracheal decellularization and Skolasinki et al. for lung decellularization 
as a basis51,52. Dissected porcine mesenteric lymph nodes were placed in 140 mL of 
deionized water in a beaker along with a stir bar (see Fig. 2.3). They were then soaked for 
1 hour on a stir plate. The deionized water was drained and replaced with 140 mL of 
0.1% v/v Triton X-100 (Sigma-Aldrich, St. Louis, MO). This mixture was stirred for 18 
hours. The Triton X-100 solution was subsequently replaced with 140 mL of 2% w/v 





sodium chloride (NaCl) for 2 hours, followed by a solution containing 30 μg/mL porcine 
pancreatic DNase (Roche Diagnostics, Basel, Switzerland), 1.3 mM magnesium sulfate, 
and 2 mM calcium chloride for another 2 hours. Finally, the samples were rinsed in 
phosphate-buffered saline (PBS) for 5 minutes by the same method. All steps occurred at 
4°C. A stir plate (PC-353, Corning) was used at a medium speed setting. Samples were 
either used immediately or stored in PBS at -80°C. 
 Decellularized tissue which was intended to be incorporated into hydrogels was 
lyophilized for 48 hours using a Freezone 6 freeze dryer (Labconco, Kansas City, MO). 
An electric coffee grinder (Bodum, Triengen, Switzerland) was used to grind the ECM 
into small pieces. These pieces were digested in 0.01 N HCl with 1 mg/mL pepsin from 
porcine gastric mucosa (Sigma-Aldrich, P6887). The solution was stirred on a stir plate 
(Corning) for 2 days at room temperature. The solution was neutralized using 0.1 N 
NaOH and then drained. The tissue was washed in PBS (see Fig. 2.3) and frozen 
overnight at -80°C. The tissue was then lyophilized a second time for 48 hours and 
ground down to a powder using the coffee grinder. Before use in 3D culture, the ECM 







Figure 2.3 Porcine mesenteric lymph nodes were cut into 2-5 mm pieces and rinsed in deionized water for 2 
hours to remove extraneous material before the decellularization process began (see left panel). Porcine 
mesenteric lymph node pieces were visibly more translucent and smaller in size at the end of the 
decellularization process (see right panel). 
 
2.6 Histology 
2.6.1 Freezing tissue blocks 
 Whole porcine lymph nodes with all connective tissue removed or decellularized 
porcine lymph node tissue pieces were placed in cylindrical aluminum foil molds 
containing Tissue-Tek O.C.T (optimal cutting temperature) compound (Sakura Finetek 
USA, Torrance, CA). These samples were flash frozen in liquid nitrogen and the resultant 
blocks were stored at -80°C until sectioning. 
 
2.6.2 Sectioning 
 O.C.T blocks containing tissue samples were allowed to equilibrate to -16°C 
inside of a Leica CM1900 cryostat (Leica Biosystems, Buffalo Grove, IL) for 20 minutes 
prior to sectioning. Blocks were sectioned into 6 μm slices between -16°C and -18°C, 





based on section quality during the cutting process. A human lymph node block was used 
to provide a positive control for primary antibody selection (see section on 
immunofluorescent staining). Sections were adhered to Fisherbrand ProbeOn Plus 
microscope slides (Thermo Fisher Scientific, Waltham, MA) and stored at -80°C or used 
immediately for staining.  
 
2.6.3 Hematoxylin & Eosin 
 After sectioning, slides were immersed in a coplin jar containing hematoxylin dye 
(Sigma-Aldrich) for 5 minutes. Slides were then rinsed in distilled water for 2 minutes. 
From there, slides were dipped once in acid alcohol (1% HCl in 70% ethanol) and rinsed 
in distilled water for another 5 minutes. Then, slides were dipped 5 times in bluing 
solution (0.2% sodium bicarbonate, 1% magnesium sulfate), 10 times in 2 changes of 
distilled water, immersed in 70% ethanol for 2 minutes, and dipped twice in Eosin Y dye 
(Sigma-Aldrich). Slides were dehydrated in 70%, 95%, and 100% ethanol and cleared in 
xylene. Coverslips (Thermo Scientific) were affixed using a permount medium (Fisher 
Scientific) and imaged using an Evos FL Auto 2 microscope on a brightfield setting at 4x, 
10x, and 20x magnification. 
 
2.6.4 Masson’s Trichrome 
 After sectioning, slides were immersed in a coplin jar containing Weigert’s iron 
hematoxylin dye (Sigma-Aldrich) for 10 minutes. Slides were rinsed for 10 minutes in 
warm, running water from the tap then dipped in distilled water 10 times each. Then, 
slides were immersed in Biebrich scarlet-acid fuschin dye (Sigma-Aldrich) for 10 
minutes followed by 10 dips in distilled water. At this point, slides were immersed in 
phosphomolybdic-phosphotungstic acid (Sigma-Aldrich) for 10 minutes and aniline blue 
dye (Sigma-Aldrich) for 10 minutes. Slides were then washed in glacial acetic acid for 5 
minutes, dipped 10 times in distilled water, and dehydrated in 95% and 100% ethanol. 





permount medium (Fisher Scientific) and the sections were imaged using an Evos FL 
Auto 2 microscope on a brightfield setting at 4x, 10x, and 20x magnifications. 
2.7 Immunofluorescence staining 
 After their removal from storage at -80°C, slides were allowed to thaw for 30 
minutes. Acetone that had been chilled to a temperature of -20°C was pipetted onto 
sections and let sit for 10 minutes. At this point, the acetone was poured off the slides that 
were then rinsed with PBS after an additional 15 minutes was given for the acetone to 
fully evaporate. A hydrophobic slide marker (MilliporeSigma) was used to draw barriers 
around each section to avoid run-off. Each section was blocked with a normal serum 
blocking solution (927503, BioLegend, San Diego, CA) for 1 hour at room temperature. 
Then, primary antibody dilutions were applied to the appropriate sections. Slides were 
placed on racks in a tin foil-wrapped box with damp paper towels to ensure a dark, humid 
atmosphere. These conditions were maintained at 4°C overnight. The next day, primary 
antibody solutions were removed and the slides were rinsed with PBS. Secondary 
antibody dilutions were pipetted onto each section and the slides were allowed to 
incubate in the dark for 2 hours at room temperature. The secondary antibody solutions 
were discarded, the slides were rinsed again with PBS, and coverslips were affixed to 
each slide using a 4′,6-diamidino-2-phenylindole (DAPI) anti-fade mounting medium (H-
1500, Vector Laboratories, Burlingame, CA). Slides were dried for 15 minutes then 
placed in a slide book and kept at 4°C overnight. Control slides containing no stain or 
secondary-only stains were incubated with PBS in place of primary or primary and 
secondary antibody dilutions to prevent dehydration. Images were taken at 4x, 10x, or 
20x magnification on the Evos FL Auto 2 microscope. The background signal of each 
channel was visually minimized, and the resultant gain was maintained throughout the 








 As a primary antibody for immunohistochemical staining (IHC), an anti-laminin 
rabbit polyclonal IgG (ab11575, Abcam, Cambridge, UK), was chosen to target multiple 
isoforms of laminin, most likely including laminins 411 and 511 (see section 3.5). This 
antibody was diluted 1:250 in the serum block, and reacted with a DyLight 594-
conjugated donkey anti-rabbit secondary antibody (711-515-152, Jackson 
ImmunoResearch Laboratories). The secondary antibody was diluted 1:500 in the serum 
block. The Evos FL Auto 2 microscope’s red fluorescent protein (RFP) channel was used 
to detect DyLight 594 fluorescence. 
 
2.7.2 Fibronectin 
 An anti-human fibronectin rabbit polyclonal IgG (H-300, Santa Cruz 
Biotechnology, Dallas, TX) was used as the primary antibody to detect fibronectin. This 
antibody was diluted 1:250 in serum block and reacted with a DyLight 488-conjugated 
goat anti-rabbit polyclonal IgG (35552, Invitrogen, Carlsbad, CA) acting as a secondary 
antibody. The secondary antibody was diluted 1:500 in the serum block. The Evos FL 
Auto 2 microscope’s green fluorescent protein (GFP) channel was used to detect DyLight 
488. 
 
2.8 Quantification of dsDNA 
 A Quant-iT (Invitrogen) PicoGreen dsDNA kit was used to quantify dsDNA 
content in native and decellularized porcine lymph node samples. The 20X TE (tris-
EDTA) buffer (Invitrogen) was diluted to a 1X working solution using sterile, distilled, 
nuclease-free water (Qiagen, Hilden, Germany). The Quanti-iT PicoGreen dsDNA 
reagent (Invitrogen) was diluted to a working volume using the 1X TE buffer and kept 
wrapped in aluminum foil to avoid photodegradation. It was used within a few hours of 





buffer. This stock solution was further diluted to 0, 2, 10, 20, 100, or 200 ng/mL using 
TE buffer to provide a standard curve. These samples were further diluted by a factor of 2 
when combined with 1 mL of reagent to produce final dsDNA concentrations of 0, 1, 5, 
10, 50, and 100 ng/mL. Native or decellularized porcine lymph node pieces were massed 
on a scale (ED124S, Sartorius AG, Göttingen, Germany). These values ranged from 5 to 
8 mg. A PRO200 tissue homogenizer (PRO Scientific) was used for 2 minutes at a 
medium power setting to release dsDNA from the tissue samples within 1.2 mL of TE 
buffer. Decellularized samples were homogenized first, and the homogenizer was cleaned 
in sterile, distilled, nuclease-free water between samples to avoid introduction of DNA 
from one sample to another. A clamshell mini microcentrifuge (USA Scientific, Ocala, 
FL) was used to spin down samples for 2 minutes and 1 mL of the supernatant was 
collected for analysis. All samples and standard curve solutions were allowed to incubate 
with the reagent for 5 minutes prior to data collection. Native tissue samples were in 
buffer by a factor of 100 to ensure that all read values fell within the standard curve. 
After mixing, 200 μL of each solution was transferred to a 96-well plate (CELLTREAT) 
and fluorescence was measured by a Cytation 3 microplate reader (BioTek, Winooski, 
VT) at an excitation wavelength of 480 and emission wavelength of 520. “Blank” wells 
containing only TE buffer and reagent provided a means of determining the background 
signal. Multiple trials were performed at once to minimize the effect of differing 
incubation times. Native and decellularized tissue samples were prepared in triplicate. 
Additional native and decellularized tissue samples were weighed, frozen at -80°C in 
PBS overnight, lyophilized using a Freezone 6 freeze dryer (Labconco) for 24 hours, and 
weighed again to normalize fluorescence values by the dry weight of the tissues.  
 
2.9 Isolation and quantification of soluble protein 
 Lyophilized and native porcine lymph node tissue samples were placed on a scale 
and each adjusted to a mass of 900 mg. A lysate buffer was prepared with 100 mM Tris 
base (Fisher Scientific), 1 mM ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich), 





Mini protease inhibitor cocktail (Roche Diagnostics). The pH of the buffer was adjusted 
to 7.4 by adding hydrochloric acid (HCl) (Sigma-Aldrich) and measuring with Hydrion 
pH test strips (Micro Essential Laboratory, Brooklyn, NY). Tissue samples were 
homogenized in the lysate buffer for 5 minutes using a homogenizer (PRO Scientific, 
Oxford, Connecticut) on its high-power setting. The final concentration of tissue in the 
buffer after blade rinses was 15 mg/mL. The mixtures were aliquoted and centrifuged at 
4000 rotations per minute (RPM) for 30 minutes. The supernatant was collected and kept 
at -80°C until analysis. The samples were delivered to the Cytokine Reference 
Laboratory). A Bradford protein assay was performed to determine the amount of total 
protein and a Luminex platform-based (R&D Systems) multiplex immunoassay was used 
to determine the type of soluble protein in each sample. The full list of analytes is present 
in appendix A.1. This assay was performed as 4 trials for both decellularized and native 
tissue. 
The standard error of each set of native or decellularized samples for a given 
analyte was calculated using Microsoft Excel. MATLAB was used to calculate the p 
value of a one-tailed t-test comparing the means of the two sets of data. The alternative 
hypothesis used for each test was that the mean of the decellularized tissue sample data 
set was lower than the mean of the native tissue sample data set. The distributions were 
not assumed to have equal variance. A critical value of α = 0.05 was considered for the 
determination of statistical significance. The low number of data points in each set (n ≤ 4) 
contributed to a high degree of variability for the distributions of many analytes. In cases 
where some of the data points in a set were below the lower limit of quantification 
(LLOQ) of the immunoassay, these samples were omitted from statistical calculations. In 
cases where one of the experimental conditions (native tissue or decellularized tissue) 
produced values above the LLOQ but the other did not, no t-test was performed. Each 
sample data set was checked for outliers. To do so, Excel was used to check for data 
points that fell outside of 3 standard deviations from the mean and MATLAB was used to 






2.10 Channel molding 
 Incubation chamber constructs were 3D-printed using room temperature-
vulcanizing (RTV) silicone (American Sealants, Fort Wayne, IN) on a Cellink BioX 
printer (Cellink). Silicone was printed out of a 27-gauge nozzle (Nordson EFD, Westlake, 
OH) attached to a 2 mL printing tube (Nordson EFD) at 180 kPa. At 50% completion, the 
print was paused to place a needle (1.5 cm long, 300 μm outer diameter) across two walls 
of the construct using tweezers. The needle was slightly impacted into the layer below 
and the print was finished. The silicone was cured overnight. The middle chambers of the 
constructs were filled with 48 μL of 10 mg/mL fibrinogen in AIM-V cell medium 
combined with 12 μL of 10 U/mL thrombin. The gels were incubated overnight at 37°C. 
At this point, the needles were carefully removed from the gels by pulling them 
horizontally through the walls of the construct, leaving behind a channel. 2 μL of Trypan 
blue dye was injected into one end of each channel and pulled through by capillary 
action. Gels were imaged by phone camera and assessed for patency (see Fig. 2.4). 
 
Figure 2.4 60 μl fibrin gels were cast around pins set into the walls of 3D printed silicone constructs. These 
constructs had a height of 1 mm. The dimensions of the central chamber were 9 mm x 5 mm. The end and 
side chambers, seen above, were intended for introduction and collection or to supply the gel with a source 






2.11 Statistical analysis 
 In cases where only two groups of data were compared, a two-sample, one-tailed, 
independent t-test was performed. The one exception to this was the comparison of PBC 
viability in fibrin hydrogel cultures with added exogenous laminins to viability in the 
standard fibrin hydrogel culture without added exogenous laminins (see Fig. 3.3). In this 
case because the data distributions were overlapping, a two-sample, two-tailed, 
independent t-test was performed. When comparing a data set to a fixed reference value, 
a one-sample, one-tailed, independent t-test was performed. When comparing multiple 
groups of data to each other, a one-way ANOVA was performed to determine whether 
there existed a significant difference between them. When a significant difference was 
found, a post-hoc Tukey’s honest significant difference (HSD) test was performed to 
determine which of the data sets were different from each other, by pairwise comparison. 
Each of the previously described tests were performed using MATLAB. All data points 
were assessed to be within three standard deviations and three median absolute deviations 









3.1 PBMC/PBC viability in 3D culture 
 It has been found that 3D culture often improves the function of cells within 
tissue-engineered constructs by providing a more biomimetic microenvironment than 2D 
culture53. Hydrogels provide a porous, hydrated material with which to build these 
constructs and are commonly used in a variety of tissue engineering approaches. With 
this knowledge in mind, a 3D culture assay was developed with L/D staining to 
determine which of two commonly used hydrogels, GelMA and fibrin, would better 
sustain PBMC viability. Cell viability in 10mg/mL fibrin gels was compared to viability 
in 8%, 10%, and 12% w/v GelMA. It was at first qualitatively determined that fibrin 
yielded better viability and so an assay comparing fibrin and 5% GelMA was performed. 
A lower density of GelMA was chosen because qualitative inspection had indicated lower 
viability in higher density GelMA. Fibrin continued to provide better results and was 
used as the hydrogel for all future 3D cultures. Another experiment was performed in 
which the concentration of fibrin gels was varied to determine whether a higher or lower 
concentration would have a favorable impact on PBC viability. 
 ECM proteins can be included in 3D cultures to improve viability and function by 
providing biochemical cues and adhesion peptides. Laminins 411 and 511 are the two 
predominant laminin isoforms found in the lymphatic vasculature of lymph nodes and 
ECM and play an important role in cell adhesion and migration17,19. These proteins were 
added to fibrin gels and compared to a laminin-free control. In another attempt to 
incorporate ECM proteins into 3D culture, porcine lymph node tissue was decellularized, 
processed, and included in fibrin gels. 
 As seen in Fig. 3.1, a comparison of the effect of fibrin gel at a concentration of 
10mg/mL to GelMA at varied concentrations on the viability of PBMCs in 3D culture 
revealed that fibrin gel produces better results at both 1 and 3 days. This difference is 
especially visible after a longer duration of culture. However, due to a lack of multiple 
trials in all conditions except fibrin and 8% GelMA at the 3-day time point, these were 





t-test showed that the mean viability of PBMCs in fibrin after 3 days was significantly 
higher than that of PBMCs in 8% GelMA at the same time point (p = 0.0028). Example 
images of PBMCs in this experiment that were stained and imaged for L/D status can be 
seen in Fig. 3.4.  
 Fig. 3.2 displays the result of PBMC viability in 3D culture in fibrin (10 mg/mL) 
and 5% GelMA at 1 and 3 days. It was determined that mean viability was higher in 
fibrin at the 3-day time point than in 5% GelMA, per a two-sample, one-tailed 
independent t-test (p = 0.0016). Due to an experimental error, only one 5% GelMA trial 
could be imaged at 3 days, and so no statistical comparison could be made with fibrin at 
the same time point. However, the mean viability of PBMCs in fibrin was higher than the 
viability of PBMCs in 5% GelMA in that trial. Similar to the previously discussed 
experiment, it appears that the difference in PBMC viability as a consequence of gel 
choice increases over time. Images of L/D PBMCs can be seen in Fig. 3.5. 
 Additional studies were done to attempt to improve the viability of PBCs in fibrin 
3D cultures, as the generally accepted value for good viability in 3D bioprinted, hydrogel 
constructs for tissue engineering is 80%. Processed ECM was included, as previously 
described, but the ECM itself became stained by the ethidium homodimer-1 and obscured 
large segments of each image (see Fig. 3.7). For this reason, this assay was discontinued, 
and no viability data was collected. The results that were produced by varying fibrin gel 
concentration and adding soluble laminin proteins (laminins 411 and 511) are displayed 
in Fig. 3.3. Adding laminins to 10 mg/mL fibrin gels decreased viability at both 1- and 3-
day time points, counter to its expected effect. A t-test confirmed that the mean viability 
of PBCs in gels with laminin was significantly less than those without after 1 day of 
culture (p = 0.0019), although the difference was not significant after 3 days (p = 0.4608). 
A one-way ANOVA was chosen to determine whether changing fibrinogen 
concentrations in fibrin gels had a significant effect on PBC viability. It was found that 
this was the case in gels that were imaged after 1 day of culture. Post-hoc analysis using 
Tukey’s HSD test revealed that the highest concentration (20 mg/mL) produced a 
significantly lower mean viability than the standard and lower concentrations (10 mg/mL 





difference in mean viability between standard and low concentrations (p = 0.4210) One-
way ANOVA did not detect a significant difference from varied concentration after 3 
days of culture (p = 0.1136), which may be due to a higher variance in viability in these 
trials. Fig. 3.6 contains example images of L/D stained PBCs for this experiment. 
 Other parameters were changed over the course of viability experimentation that 
were not directly tested with controlled comparisons but may have led to an increase in 
PBC viability. Earlier experiments had a lower seeding density than later ones (from 
250,000/mL in the fibrin vs. varied GelMA concentration assay to 20 mil/mL in the assay 
with varied fibrinogen concentration and addition of laminins), which could have resulted 
in the overall improvement of viability that can be seen in Fig. 3.6. Additionally, the 
method of obtaining cells changed from separating left-over PBMCs from microbeads to 
separation of PBCs directly from peripheral blood that had been drawn only hours before 
use of these cells. The lower time in between isolation and use could have caused less 
stress to these cells and improved their viability in culture. Furthermore, the assay in 
which fibrinogen concentration was varied was performed using the same volume as 
previous experiments but in a 24 well plate instead of a 48 well plate.  This resulted in a 
thinner gel, effectively reducing the distance of diffusion for media-based nutrients to 
reach the cells. Finally, in this last experiment, the culture media was changed every 24 







Figure 3.1 PBMC viability mean values after 1 or 3 days in fibrin gels or gelatin methacrylate gels 
of varied density. The 3-day viability means for fibrin and 8% GelMA were different to a statistically 
significant degree, with fibrin producing higher viability. Group bars without error bars contained only one 
sample, n = 2 for all other groups.  
 
Figure 3.2 PBMC viability mean values after 1 or 3 days in fibrin gels or 5% gelatin methacrylate 
gels. The 3-day viability means for fibrin and 5% GelMA were different to a statistically significant degree, 
with fibrin producing higher viability. Group bars without error bars contained only one sample, n = 2 for 







Figure 3.3 PBC viability mean values after 1 or 3 days in fibrin gels of varied concentrations and 
with or without the addition of exogenous laminins 411 and 511. Brackets with stars indicate viability 
means that are different to a statistically significant degree. All group bars represent the mean viability of 







Figure 3.4 PBMCs in fibrin gels or gelatin methacrylate gels of varied concentration. Stained and 






















Figure 3.5 PBMCs in fibrin or gelatin methacrylate gel. Stained and imaged for L/D (green = live 








Figure 3.6 PBCs in fibrin gel of varied concentration, with or without the addition of exogenous laminins 
(411 & 511). Stained and imaged for L/D (green = live cells, red = dead cells) after 1 or 3 days of culture. 







Figure 3.7 PBCs in fibrin gel containing decellularized, processed porcine lymph node ECM. 
Stained and imaged for L/D (green = live cells, red = dead cells) after 1 day of culture. Lymph node ECM 
is visible as faint, diffuse, red areas surrounding PBCs (see arrow). Scale bar = 500 μm. 
 
3.2 Quantity of dsDNA in native and decellularized tissues 
 To avoid immunorejection, it is important to remove xenogeneic genetic material 
from tissues that are intended to be used as part of a tissue-engineered construct that is 
intended for in vitro use with human cells or for implantation29. In this case, porcine 
genetic material needed to be removed from porcine lymph node ECM that could then be 
included in a lymph node model containing human immune cells. The decellularized 
ECM provides key biomechanical and biochemical signals that can be difficult or 
expensive to obtain from other sources. Among the widely accepted criteria that define 
sufficient decellularization is the requirement that the decellularized tissue contain less 
than 50 ng of dsDNA per mg (dry weight) of ECM29. For these reasons, the dsDNA 
content of decellularized porcine lymph node tissue was quantified using a PicoGreen 






 The assay was performed multiple times using the standard, a blank well with no 
reagent, three decellularized tissue samples, and three native tissue samples. The standard 
ladder was changed to include the following concentrations of dsDNA: 100 ng/mL, 50 
ng/mL, 10 ng/mL, 5 ng/mL, 1 ng/mL, and 0 ng/mL. Furthermore, in subsequent analysis 
of the data, the fluorescence output of the 0 ng/mL standard well (essentially, the 
background signal) was subtracted from all output values in each trial. Due to concerns 
about contamination of decellularized samples due to carryover from the homogenizer, a 
cleaning procedure was developed to be performed in between the processing of each 
sample (see section 2.8). Lyophilization of another decellularized sample was performed 
to determine the dry weight of the ECM as compared to its wet weight. 
 The 0 ng/mL fluorescence output was subtracted from each fluorescence value for 
the standard and samples. The standard values were plotted in Excel (fluorescence vs. 
known concentration of dsDNA) with a linear fit (R2 = 0.9997). The linear function was 
used to calculate the dsDNA concentration of all samples. The mass of the tissue from 
which each sample was extracted was converted to a concentration (mg/mL) based on the 
constant solvent volume used for each extraction. The concentration of dsDNA was 
divided by the tissue concentration to produce a value with units of ng/mg (nanograms of 
dsDNA per milligram of wet tissue). The mean value and standard error for each 
condition was calculated and a two-sample, one-tailed, independent t-test determined that 
the native tissue samples contained significantly more dsDNA than the decellularized 
tissue samples (see Table 1). The ratio of wet weight to dry weight for decellularized 
tissue, determined by lyophilization, was used to convert each decellularized sample’s 
units to nanograms of dsDNA per milligram of dry ECM. The mean and standard error of 
these values were calculated. A one-sample, one-tailed t-test found that the decellularized 
samples contained significantly less dsDNA than the accepted maximum limit of 50 
ng/mg (dsDNA to dry weight ECM), indicating that this criterion for decellularization 






Table 1. Mean DNA Content of Tissue Samples 
Native Porcine Lymph Node 156.5 ± 48.9* (ng dsDNA/mg tissue [wet 
weight]) 
Decellularized Porcine Lymph 
Node 
1.0 ± 0.2* (ng dsDNA/mg tissue [wet weight]) 
* It was determined that the value in the upper row is significantly greater than the value in the 
lower row by using a one-tailed, independent, two-sample t-test. The result of this test was that p = 
0.0049 (α = 0.05). 
 
Table 2. Mean DNA Content of Decellularized Tissue Sample Compared to the DNA Content Reference 
Criteria for Tissue Decellularization 
Maximum DNA Content Criteria 50.0* (ng dsDNA/mg tissue [dry weight]) 
Decellularized Porcine Lymph Node 9.0 ± 1.9* (ng dsDNA/mg tissue [dry 
weight]) 
*It was determined that the value in the upper row is significantly greater than the value 
in the lower row by using a one-tailed, one-sample t-test. The result of this test was that p 
= 1.9222x10-6 (α = 0.05). 
 
3.3 Collagen and cellular content in native and decellularized 
tissues 
 The process of decellularization, while necessary to remove native genetic 
material to avoid immunorejection, has the potential to degrade ECM proteins. As 
mentioned previously, these proteins provide important biochemical and biomechanical 
signals to cells that can aid in maintaining viability and function. In particular, collagen 
forms a structural basis for the lymph node and contains bioactive domains that enable 
cellular adhesion and migration. For these reasons, it was decided that hematoxylin and 
eosin (H&E) as well as Masson’s trichrome staining would be used to evaluate the matrix 
integrity and presence of collagen in native and decellularized porcine lymph node tissue 





was a part of the chosen formulation of Masson’s trichrome were used to visualize the 
presence of cells in these sections. 
 H&E and Masson’s trichrome staining were done on O.C.T.-embedded tissue 
samples. Whole, native porcine lymph node sections were used to provide a positive 
control to compare visually with decellularized sections. Imaging was done at multiple 
magnifications to observe tissue structures of various sizes and to determine whether the 
impact of decellularization had spatial variation.  
 Images were visually compared for the quantity and density of collagen, which 
was stained pink in H&E slides and blue in Masson’s trichrome slides. In Fig. 3.8, it is 
apparent from panel d that collagen of significant quantity and density is present in 
decellularized porcine lymph node tissue. Cells can be observed in panels a and c, which 
correspond to the native lymph node section at different magnifications. Comparing this 
with the two panels on the right, it is clear that decellularization thoroughly removed cells 
from the ECM, as intended. These findings are corroborated by Fig. 3.9, in which cells 
are also visible (in dark brown dye) in the left two panels that display native tissue but are 
not present in the decellularized tissue displayed on the right. Furthermore, the collagen 
fibers that are shown (in blue) in panels b and d are dense and intertwined. It is difficult 
to determine whether the overall amount and density of collagen fibers is decreased by 
decellularization, but it is apparent that decellularized porcine lymph node tissue retains a 
significant amount of this ECM. This is consistent with what has been reported by our lab 
for the decellularization of porcine lung tissue30. It should be noted that the eosin 
component of H&E (the light pink dye) can also stain elastic fibers, which are present in 
the lymph node ECM, although in lesser abundance than collagen54. It should also be 
noted that these stains do not identify specific types of collagen, and that an analysis of 






 Figure 3.8 Brightfield images of tissue sections stained with H&E. In panel a, solid circle shows follicle, 
dashed circle shows paracortex, solid arrow shows capsule and SCS, and dashed arrow shows trabecula 
(afferent vasculature). In panel b, sold circle shows the central vein and dashed circle shows an arteriole. 
Tissue type and magnification are displayed on the top and left sides of the figure. For 4x, scale bars = 1000 






Figure 3.9 Brightfield images of tissue sections stained with Masson’s Trichrome. Collagen and connective 
tissue are in blue and cells are in dark gray. Tissue type and magnification are displayed on the top and left 
sides of the figure. Solid circles indicate vessels and dashed circle indicates artery. For 4x, scale bars = 
1000 μm; for 20x, scale bars = 200 μm. 
 
3.4 Laminin and fibronectin in native and decellularized 
tissues 
 For reasons mentioned in section 3.4, it is ideal to preserve ECM proteins while 
decellularizing tissue. Several isoforms of laminin are found in lymph node ECM and 
have been shown to impact immunological function. Isoforms 332, 411, and 511 are 
among the most prevalent of these. To determine whether laminin content and structure 
was preserved in decellularized porcine lymph node tissue, IHC staining was performed 
on tissue sections. Initially, three different primary antibodies were selected to detect the 





Due to poor fluorescent signals from the antibodies that were selected to detect 
laminin alpha chains α3 and α4, the results of those experiments are not shown. It is 
likely that the dilution of the primary and/or secondary antibodies would need to be 
optimized to provide better results. It should be noted that the immunogen from which 
the anti-laminin rabbit polyclonal IgG used to detect laminin isoforms in this experiment 
was produced (see section 2.8.1) was laminin from basement membrane tissue of 
Engelbreth Holm-Swarm (EHS) mouse sarcoma. The laminin isoform purified from EHS 
sarcoma is laminin 111, which, although distinct from other isoforms in its entire 
structure, shares β and γ chains with some of them (notably 411 and 511, but not 332)55. 
For this reason, these antibodies have the potential to bind to a variety of laminins, but 
not necessarily all that are important to the function of immune cells within the lymph 
node55. In future studies, specific isoforms of laminin could be detected by using and 
optimizing the dilution of primary antibodies that bind to specific alpha chains. 
 Product information for the primary antibody showed that it has been validated as 
having species reactivity with human laminins but not porcine laminins. As the tissue 
being decellularized and analyzed was porcine, it was decided that to determine whether 
or not there was a loss in signal due to differences in species reactivity, human lymph 
node sections were to be used as a positive control. Sections stained with only secondary 
antibodies and unstained sections were used as negative controls to detect non-specific 
staining and autofluorescence, respectively.  
 Fibronectin was chosen as another key ECM component to detect via IHC due to 
its prevalence in lymph node tissue and roles in promoting cellular adhesion and 
migration. The anti-human fibronectin rabbit polyclonal IgG primary antibody that was 
chosen to detect fibronectin was validated for use in IHC, according to product 
information. It is specific to human fibronectin and therefore warranted the use of a 
similar comparison with human lymph node tissue. Similar negative controls were used. 
  From the tissue sections that were stained with primary antibodies reactive to 
laminins of multiple isoforms (see Fig. 3.10), a clear fluorescent signal was obtained in 
human, native porcine, and decellularized porcine lymph node sections. There does not 





fact, the signal obtained by imaging decellularized tissue appears to be stronger than in 
the other cases. It may be that decellularization exposes laminin domains that are bound 
to cells in native tissue, resulting in a greater total number of bound antibodies and a 
stronger signal. A look at Fig. A.2.1 in Appendix A.2 to compare this result with its 
negative controls confirms that the fluorescent signal is highly specific. 
 Fig. 3.10 also displays the results of incubating human, native porcine, and 
decellularized porcine tissue sections with antibodies against human fibronectin. Here, it 
is clear by comparing panels a and b that there is a significant difference in signal 
strength between human and porcine samples, indicating that the primary antibody used 
for this assay has higher affinity for human fibronectin. Even so, it can be observed by 
comparing panels b with the negative control images in Fig. A.2.2, Appendix A.2, that 
there is a specific signal associated with native porcine tissue. This signal is mostly lost in 
decellularized sections, indicating that this process results in a loss of binding sites for 






Figure 3.10 Fluorescence images resulting from IHC antibody staining to detect laminin and fibronectin, 
and DAPI counterstaining to detect nuclear material. The type of tissue section is displayed at the top of 
each panel column. All scale bars = 500 μm. 
 
  
3.5 Nuclear material in native and decellularized tissues 
 In addition to the criterion that decellularized tissue contains less than 50 ng of 
dsDNA per mg of dry ECM, it is accepted that nuclear material should not be visible in 
decellularized tissue sections when subjected to a DAPI stain29. DAPI is a popular 
nuclear stain due to its ability to bind to adenine-thymine regions of dsDNA and emit a 
fluorescent signal56. 
 During the process of detecting specific ECM proteins in native and 
decellularized porcine lymph node tissue through IHC, each section was also imaged to 





seen that the native porcine section contains bright blue dots distributed throughout the 
tissue, indicating the presence of cells. On the other hand, the decellularized section lacks 
specific DAPI staining and, by extension, significant cellular content. This upholds 
additional criteria for sufficient decellularization of these tissues. 
  
3.6 Cytokines in native and decellularized tissues 
 Soluble growth factors and cytokines that are sequestered in porcine lymph node 
tissue could serve to improve leukocyte viability and function in an in vitro human lymph 
node model. A protein extraction assay was performed to determine whether certain 
porcine growth factors and cytokines remained within porcine lymph node tissue after 
decellularization. Soluble protein content in decellularized samples was compared to that 
of “native” (not decellularized) porcine lymph node tissue to observe changes due to 
decellularization. A panel of human analytes was used to perform a Luminex multiplex 
immunoassay in the Cytokine Reference Laboratory. Although the proteins contained in 
the tissue samples were porcine in origin, it was decided that they might have a suitable 
degree of homology to the equivalent human sequences to be detected by the 
immunoassay and provide beneficial signals to human leukocytes in 3D culture. A 
Bradford assay yielded the total protein concentration in each sample while the 
immunoassay determined specific analyte concentrations in each sample. In some cases, 
the concentration of a specific protein in the sample was too low for detection. The 
analytes included in the panel are listed in appendix A.1. 
 The total protein values from the Bradford assay were used to normalize the 
analyte concentration results in each sample (see Tables 3 and 4). Four samples of both 
decellularized and native tissue were prepared to assess variability and develop more 
reliable statistics.  
 In general, it appears that decellularization of porcine lymph node tissue decreases 
the relative amount of growth factors and cytokines present (see Table 3). In many cases, 





fibroblast growth factor 2 (FGF2), the beta subunit of interleukin 12 (IL-12p40), 
interleukin 1 beta (IL-1β), and interferon gamma-induced protein 10 (IP-10), the decrease 
in relative amount of the protein after decellularization was statistically significant. The 
comparison of the other analytes displayed in Table 3 did not indicate a statistically 
significant decrease in concentration from decellularization. The single exception to the 
categories previously mentioned is the case of the relative amount of vascular endothelial 
growth factor (VEGF). The data indicate that an amount of VEGF that exceeded the 
detection limit was present in decellularized samples but not in native ones. It should be 
noted that, in cases in Table 3 where standard error is not displayed with the mean values, 
there was only one sample with a result that was above the LLOQ. 
 
Table 3. Bradford Assay Results for Total Protein in Native and Decellularized Porcine Lymph Node 
Tissue Samples 
Mean Total Protein Concentration in 
Native Tissue Samples 
Mean Total Protein Concentration in 
Decellularized Tissue Samples 
0.12 ± 0.03 mg/mL 
 
0.26 ± 0.07 mg/mL 
 
Table 4. Luminex Multiplex Immunoassay Results for Analyte Concentration in Native and Decellularized 
Lymph Node Tissue Samples 
Analyte Native Tissue Sample 
Mean Concentration 
(pg/mg total protein) 
Decellularized Tissue 
Sample Mean Concentration 




FGF-2 61677.27 ± 14570.99 2771.95 ± 555.19 0.0034 
TGF-α 23.00 ± 6.88 <LLOQ n/a 
FLT-3 ligand 567.23 ± 180.06 <LLOQ n/a 





IFNα2 24558.86 ± 14161.22 266.99 ± 48.96 0.0685 
IL-10 10.19 ± 3.43 <LLOQ n/a 
IL-12p40 346.65 ± 95.06 115.14 ± 29.65 0.0295 
IL-13 31031.60 ± 16514.19 115.11 ± 38.83 0.0552 
IL-15 28.47 ± 8.13 <LLOQ n/a 
IL-17A 14.40 ± 4.12 7.47 ± 2.06 0.1790 
IL-9 31.29 ± 8.21 17.78 ± 3.79 0.0928 
IL-1β 18.48 ± 4.27 6.81 ± 1.71 0.0222 
IL-2 5.50 ± 2.39 <LLOQ n/a 
IL-3 2.34 ± 0.85 2.04 ± 0.54 0.3842 
IL-6  7.10 <LLOQ n/a 
IL-7 13.91 ± 9.29 <LLOQ n/a 
IL-8 6.49 ± 1.14 <LLOQ n/a 
IP-10 62.18 ± 13.65 29.24 ± 3.04 0.0500 
VEGF <LLOQ 2511.87 ± 497.80 n/a 
 
3.7 Channel development in hydrogels for vascularization 
 LECs form the lining of lymphatic vessels and perform a variety of signaling 
functions that enable the migration of immune cells and the uptake of pathogenic 
antigens. A functional human lymph node model requires lymphatic vasculature both for 
biomimetic functionality and as a way of introducing molecules or cells for 
experimentation. In a study by Meng et al., published in 2019, channels were created for 
subsequent endothelialization by pulling pins from a fibrin hydrogel-containing silicone 
structure57. Endothelial cells were introduced to the space left behind via injection and 
capillary action57. Furthermore, VEGF was placed within the hydrogel to promote vessel 





This same approach could be used to vascularize an in vitro lymph node model using 
LECs. 
 Silicone constructs were printed as previously described in section 2.10. The 
model was designed based on dimensions used in the study by Meng et al., but modified 
for the desired application by changing the configuration of the chambers. Optimal 
printing parameters were chosen by varying print speed, infill density and pattern, and 
layer height and visually observing the structural integrity of the resultant constructs. 
Varying volumes of fibrinogen were pipetted into these constructs to determine the 
minimum volume that would provide even coverage of the space. This was determined to 
be 60 μL. The initial concentration of thrombin used in these gels was 0.5 U/mL. The 
mixture was pipetted thoroughly and incubated at 37°C for 30 minutes. The gels were 
inspected at this time and found to still be liquid at their centers, with a crosslinked, 
firmer shell around them. They were allowed to incubate for an additional 90 minutes, 
without significant changes. The concentration of thrombin was changed to 1 U/mL or 2 
U/mL for an additional two sets of gels. These were incubated overnight. It was observed 
that the 1 U/mL gels still failed to solidify sufficiently. The 2 U/mL gels appeared to be 
much firmer and were selected to have the pins were removed from them. It is unclear 
why the initial concentration of thrombin (0.5 U/mL) did not gel sufficiently or why a 
much longer incubation period was required, because the reference study used this 
concentration and observed rapid gelation with it57. One possibility is batch variation in 
thrombin, but solutions from two different shipments were used in this screening test, and 
there was no obvious difference in gelation time. Figure 3.11 displays the result of the 
attempt to perfuse the channels with Trypan blue, per the method described in section 
2.10. Trypan blue was chosen for its high color contrast with the fibrin gel, allowing clear 
visualization of the degree of perfusion and patency of the channels. 
Of the four gels that were prepared, only one contained a fully perfusable, well-
defined channel (see Figure 3.11, circled). The others contained channels that partially 
collapsed. It was observed that in some of these cases, the action of pulling the pin from 





silicone walls and possibly caused tearing within the gel itself. This may have left spaces 
for dye to flow into, without following the course of the channel. A visual indication of 
this result may be the sections of gel in which the dye is not contained in a well-defined 
space and appears to have “bled” into other portions (see Figure 3.11, arrow). It is worth 
noting that when perfusion was not achieved from injection of the dye at one end of the 




Figure 3.11 Silicone constructs containing fibrin gels from which pins have been removed and the resultant 
channels perfused with Trypan blue dye. The circled construct contains a well-defined, fully perfused 











4.1 Fibrin hydrogels provide a promising 3D scaffold for 
PBMC/PBC culture but can be further optimized 
 As previously stated, hydrogels provide an effective means of 3D culture in the 
form of a porous, hydrated, and modifiable microenvironment. Comparisons of PBMC 
viability in fibrin and GelMA hydrogels after 1 and 3 days were made to determine which 
material would better support an in vitro lymph node model. Viability analysis was 
somewhat limited in that cell counting was performed manually and was therefore subject 
to a degree of human error. An initial attempt to use ImageJ to automate the process and 
limit bias failed due to L/D stain background noise, dense cell clustering, and the 
irregularity of apparent cell size from imaging out-of-focus cells whose focal planes were 
not included in the chosen z-stack. These issues could be partially addressed in future 
studies by casting thinner gels of more consistent thickness and optimizing the duration 
of L/D stain incubation to limit background noise while brightly staining cells.  
It was determined that fibrin maintains PBMC viability better than GelMA of any 
of the chosen concentrations, especially at longer culture durations (see Figs. 3.1 and 
3.2). While the difference is only statistically significant at 3 days when comparing fibrin 
to 5% and 8% GelMA, this is likely due to experimental errors that resulted in single 
trials of certain conditions such that no population variance could be assessed. To 
strengthen these results, it would be necessary to repeat these experiments with several 
trials of each condition and time point. However, the stark differences that do exist 
between the viabilities assessed for each gel type after 3 days of culture indicate that 
fibrin is more capable of supporting PBMCs. This may be due to the engagement of 
fibrin with leukocyte integrin Mac-1, expressed by monocytes, dendritic cells, NK cells, 
and some subsets of B and T lymphocytes58,59. CD11d, another leukocyte integrin that is 
similar to Mac-1 and expressed by monocytes, NK cells, B cells, and some T cells, also 
binds to fibrin60. These binding events, in addition to cellular surface integrin interactions 
with the RGDS and γ-chain AGDV binding motifs contained in fibrin, may impart fibrin 





popular choice of hydrogel in studies regarding attempts to engineer lymph nodes or 
other peripheral lymphoid organs (see section 1.4), Ferreira et al. used fibrin gels to 
support the proliferation of hematopoietic stems cells and multiple other studies have 
shown that fibrin gels can support significant lymphangiogenesis with LECs62,63,64,65. 
After deciding on fibrin as the base hydrogel material for continued assays, an 
experiment was conducted to assess the effect of varied fibrinogen concentrations on 
PBC viability. The addition of laminins 411 & 511 was also compared to a control as 
these were expected to improve viability by providing binding motifs and key signals to 
the lymphocytes within. PBCs within 20 mg/mL fibrin gels had significantly lower 
average viability after 1 day of culture than those in 5 and 10 mg/mL fibrin gels (see Fig. 
3.3). Despite this, PBCs in the higher concentration gels maintained a higher average 
viability over 3 days of culture. This difference was not significant, likely due to the 
higher variance in viability after 3 days. This experimentation could be repeated with 
more trials to achieve higher statistical power and possibly detect significant differences. 
While the trends remain mostly unclear, the lower viability in high concentration gels 
after 1 day of culture may be due to decreased diffusion of nutrients through the gel and 
this disadvantage may be removed over time due to ECM remodeling. In opposition to 
expectations, the PBCs in fibrin gels that were supplemented with laminins had a 
significantly lower average viability after 1 day of culture (see Fig. 3.3). In addition to 
laminin 511 promoting adhesion and migration in lymphocytes, both isoforms also play a 
role in T cell proliferation and activation19. It is possible that increased T cell 
proliferation in these hydrogels was not sufficiently supported by the nutrient supply, 
leading to pockets of cell starvation and death. To better understand the dynamics of 
leukocyte proliferation and death in fibrin gels, a combination 3-(4,5-dimethylthiozol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays 
(see section 4.4 for more detail) could be performed. Alternatively, hydrogels could be 
fixed, sectioned, and subjected to anti-Ki67 IHC, as this protein is a marker of cell 
proliferation and has been used to detect the proliferation of lymphocytes66. Finally, the 
hydrogels could simply be subjected to L/D staining multiple times over the culture 





death. One concern with this approach is the need to accurately track cells, requiring an 
imaging location with set boundaries to distinguish between the contribution of migration 
and proliferation to cell counts. It is also possible that imaging would have to be 
performed more often to identify migratory and proliferative behavior. It should also be 
noted that the change from using PBMCs to using PBCs during experimentation 
introduced new cell populations, namely granulocytes. Because cell viability was 
assessed as a whole, it is not clear whether some cell populations were better maintained 
than others over time or with changes in hydrogel type and density. Future studies would 
benefit from assays in which cells are separated by phenotype after culture and 
population viabilities are assessed individually (see section 4.6 for more detail). 
Some changes were made between viability assays that were not strictly 
controlled for or directly compared, but which may have made a positive impact on 
leukocyte survival. For one, higher seeding densities were implemented in later assays 
due to changes in PBMC/PBC acquisition methods that led to higher cell numbers. This 
may have resulted in the relatively higher viability of PBCs in Fig. 3.3, as opposed to 
Figs. 3.1 and 3.2, due to cell-cell signaling that promotes survival. On the other hand, a 
high seeding density can lead to an oxygen consumption rate that exceeds the transport of 
oxygen through the hydrogel and leaves some areas hypoxic67. To be sure that this 
change improved viability, further tests would need to be performed in which all other 
conditions are held constant while seeding density is varied. Furthermore, this experiment 
used the same volume (220 μL) as previous assays, but in a 24-well plate instead of a 48-
well plate. This resulted in thinner gels with lower diffusion distances for nutrients from 
culture media. Again, this change would be to be directly compared to thicker gels to 
confirm its impact. One assay (not presented here) was done with 22 μL gels, but these 
small volumes were deposited as droplets with radii that did not appear significantly 
smaller than the thickness of larger volume gels that spread across the well. Furthermore, 
qualitative inspection of PBC viability after 1 day of culture did not reveal obvious 
improvements, and so this approach was not continued in later assays because larger 
volumes were easier to work with and facilitated a more even distribution of PBCs. It is 





serious decreases in leukocyte viability over time. Purwada et al. maintained B cells for 6 
days in 10 μL static gel culture whereas Sardi et al. maintained lymphocytes for 21 days 
in a perfusion bioreactor41,68. For this reason, future studies would likely need to find a 
way to implement far smaller volumes or the use of a bioreactor to ensure sufficient 
nutrient transport. As stated before, vascularization of these hydrogels would provide an 
even better and more biomimetic means of accomplishing this goal. 
4.2 Porcine lymph node tissue can be decellularized but needs 
further characterization of remaining nuclear material 
 As previously mentioned, cells and nuclear material must be removed from 
allogeneic tissues that are intended to be used with human cells or implanted to avoid 
immunorejection29. The method used to produce the decellularized porcine lymph node 
tissue analyzed in this study uses the surfactants triton X-100 and sodium deoxycholate in 
conjunction with DNase I to lyse cells and degrade DNA. The benefit of this choice of 
reagents is that they are known to cause minimal damage to the tissue ECM. Sodium 
deoxycholate can be less effective at full decellularization but, in this case, is combined 
with triton X-100 to provide multiple wash cycles. This method was modified slightly 
from that which was published by Galliger et al. for the decellularization and digestion of 
tracheal tissue for use in GelMA hydrogels51. While this combination of reagents has 
been previously used to decellularize lung tissue by perfusion, Galliger et al. adapted it to 
the decellularization of small pieces of tracheal tissue intended for additional processing 
and hydrogel incorporation for 3D cell culture51,52. Other researchers have compared the 
use of SDS, CHAPS, or Triton X with deoxycholic acid for the decellularization of 
lymph nodes and found that SDS provided full decellularization while maintaining 
collagen and reticular fibers, thereby deeming it the best option69. However, SDS 
treatment is known to denature proteins in the ECM and while fiber structures may have 
been maintained, as ascertained by histology, it was not clear whether this approach 
would destroy important bioactive molecules and binding sites31,69. Furthermore, the 
authors mentioned that SDS may have been more effective in decellularization of whole 





lymph nodes were cut into smaller pieces, effectively disrupting the capsule and its 
resistance to diffusion69. Similarly, Lin et al. compared the efficacy of a variety of acids 
on the decellularization of whole lymph nodes50. While they found that formic acid 
delivered sufficient decellularization and preserved collagen and glycosaminoglycans 
(GAGs), this finding is directly in conflict with other studies that have found that acid 
treatment tends to damage collagen and GAG content31. Lin et al. provided a similar 
explanation, suggesting that formic acid effectively permeates the fibrous capsule of 
whole lymph nodes50. 
 Assessment of dsDNA content via PicoGreen assay found that porcine lymph 
node tissue that was decellularized by the methods described in this paper contained 
significantly less dsDNA than the accepted upper limit of 50 ng/mg ECM (dry weight)29. 
One potential caveat to this result is that time of homogenization (to release dsDNA), 
while kept the same between decellularized and native tissue samples, was not varied to 
determine whether there was a significant effect of duration on dsDNA detection. For 
validation purposes, future studies could look at the effect of homogenization duration on 
dsDNA concentration and determine what the minimum time to release nearly all of the 
dsDNA from tissue samples would be. This could be decided by observing at what point 
the additional time of homogenization no longer resulted in significant changes to 
dsDNA release.  
 Staining of decellularized porcine lymph node tissue sections with DAPI did not 
result in any clearly visible nuclear material (see Fig. 3.10). The last addition to 
experimentation to fully meet the requirements of sufficient decellularization would be to 
verify that any remaining dsDNA fragments are less than 200 bp in length. Flow 
cytometry can detect dsDNA lengths down to about 125 bp by staining the dsDNA with 
fluorescent, intercalating dyes whose total output is linearly dependent on the fragment 







4.3 Decellularized porcine lymph node tissue maintains some 
ECM proteins and relevant cytokines 
 The ECM of the lymph nodes contains diverse proteins with bioactive and 
structural functions that can be incorporated into 3D hydrogel scaffolds to support 
encapsulated leukocytes. To determine whether decellularization removed key proteins 
from the ECM, histology and IHC were performed on native and decellularized lymph 
node tissue. To determine whether soluble cytokines and chemokines remained 
sequestered in the ECM after decellularization, a Luminex multiplex immunoassay and 
Bradford assay were performed on the same tissues.  
 A visual analysis of collagen content in H&E and Trichrome-stained tissues in 
Figs. 3.8 and 3.9 reveals a dense network of the protein even after decellularization. 
Collagen contains the cell binding motif, GFOGER, and is a key structural component of 
the ECM71. Lin et al. and Cuzzone et al. both looked at the collagen content of 
decellularized lymph nodes, histologically, before using them as scaffolds for therapeutic 
immune cells50,69. The primary drawback to detecting collagen using H&E or Trichrome 
is a lack of specificity since distinct collagen subtypes are not identifiable this way. 
Further studies would benefit from using IHC with antibodies against the primary 
collagen subtypes that are present in the lymph nodes. 
Comparing native and decellularized porcine lymph node tissue sections in 
Fig.3.10, it can be seen that there was no loss of signal from antibodies with a general 
specificity for laminin as a consequence of decellularization. In fact, these decellularized 
sections actually appear brighter; this may be due to the uncovering of laminin binding 
sites through the loss of cells that would have otherwise occupied them. Antibodies that 
were specific to laminin chains α3 and α4 had been used in experimentation, but those 
results are not shown due to weak signals across each condition that do not reveal 
significant differences. This may be a consequence of an over-dilution of primary or 
secondary antibodies, and future studies could home in on their ideal concentrations to 
yield more usable results. These findings would be impactful, as laminins 332 and 411 
have significant and distinct interactions with immune cells that would ideally be 





IHC with antibodies against laminin chain α5, as this could detect the equally important 
511 isotype. 
 The observation of lymph node sections stained for fibronectin, visible in Fig. 
3.10, reveals that there is a loss of specific signal in porcine lymph nodes as a result of 
decellularization. This indicates that the fibronectin binding sites that the antibody 
recognizes have been lost or altered and may indicate that there is an overall loss or 
alteration of fibronectin due to decellularization. However, this is not necessarily true, as 
the epitope against which the primary antibody was produced is at the C-terminal of the 
protein, whereas fibronectin contains cell-binding motifs in its central regions72. It is also 
notable that there is a significant interspecies difference in primary antibody binding. 
Since the antibody was produced using human fibronectin, it has more affinity for human 
lymph node tissue and produces a stronger fluorescent signal. While human and porcine 
fibronectin are highly homologous (93%), this would indicate a difference in C-terminal 
peptide sequences73. It is not clear whether porcine fibronectin would be similarly less 
effective at binding human leukocytes. Theodore et al. found that porcine PBMCs bind to 
human fibronectin but did not perform the reverse experiment74.  
 From Table 3, it can be seen that relatively few cytokines that were detectable in 
native tissue remained so in decellularized tissue. The presence of several important 
interleukins, including IL-2, IL-6, IL-7, and IL-15, was significantly decreased in 
decellularized samples. Several analytes in the panel were not detectable in either native 
or decellularized tissue samples, including chemokine CXCL1 and B-cell activating 
molecule CD40L. Future studies could increase the time of tissue sample homogenization 
to potentially release more cytokines from the ECM, similar to the method described in 
section 4.2. There are several key cytokines and chemokines that have a large impact on 
lymph node functionality that were not included in this panel. CCL19 and CCL21, whose 
functions are described in detail in section 1.1, have been used in a microfluidic platform 
and a collagen-PEG hydrogel, respectively, to study T cell migration and activation75,76. 
CXCL12 and CXCL13 also contribute to lymphocyte migration and could be included in 
an expanded, future panel. IL-21 and BAFF support B cell survival. Engineered stromal 





formation in hydrogels41. Finally, IL-4, though not included in this panel, induces 
proliferation of activated B cells, and was also used by Purwada et al. to achieve these 
goals41. One interesting observation is that there was more detectable VEGF in 
decellularized samples than native ones. This observation is consistent with other studies 
of cytokine content in decellularized renal and vascular tissue77,78. It is likely that VEGF, 
which is bound too tightly to native ECM to be detected by the assay, was released by 
degradation of its binding sites by some step of the decellularization process.  
One limitation of this experiment was the high degree of variance found in the 
data. Increasing the number of trials per condition would allow an improved statistical 
detection of differences and make the results more accurate and meaningful. Another 
aspect to consider is that a panel for human analytes were used in the immunoassay. 
Differences in human and porcine homology may have contributed to some cytokines not 
being detected. On the other hand, those that were detected likely have closer homology 
and therefore may be more recognizable by human immune cells such that they impart 
the desired bioactivity. 
To achieve a sufficient level of functionality in a tissue engineered lymph node 
model, it may be necessary to supplement fibrin-encapsulated leukocytes with exogenous 
soluble cytokines or to co-culture them with cytokine-producing stromal cells. While 
much of this role is filled by lymph node stromal cells, namely FRCs and FDCs, in vivo, 
these cell lines are difficult to isolate, such that some research groups have chosen to 
develop custom stromal cell lines79. While many studies have relied on exogenous 
supplementation, Purwada et al. engineered a custom stromal cell line to produce BAFF 
and CD40L, and Sardi et al. differentiated mesenchymal stromal cells (MSCs) into a 
stromal line with similarities to lymph node stromal cells to recreate the signaling 
provided by those cells41,68. The continuation of the studies presented here would 
potentially require the selection or creation of a stromal cell line to support leukocyte 






4.4 Incorporating decellularized tissue into hydrogels requires 
additional experimentation 
 As stated before, decellularized ECM can contain a wide variety of adhesion 
ligands and sequestered cytokines. The complexity of signals present in the ECM of the 
lymph nodes would be difficult to fully recapitulate in vitro from base materials. A 
number of studies in the literature that used hydrogels to culture immune cells and 
achieve peripheral lymphoid organ function used collagen (containing the GFOGER cell 
binding motif) or another polymer modified with a single cell binding sequence. Sardi et 
al. modified dextran with RGD peptides, while Purwada et al. functionalized maleimide-
polyethylene glycol hydrogels with RGD or GREDV peptides41,68. While inclusion of a 
single binding motif is an improvement over hydrogels with none present, the ECM of 
the lymph node contains several proteins with a variety of binding motifs. This 
complexity could be relatively easily obtained by incorporating decellularized, processed 
lymph node ECM into fibrin hydrogels. This was attempted by including 10 mg/mL of 
ECM that had been decellularized, ground, and digested with pepsin into fibrinogen 
solutions that were used to form hydrogels for 3D PBC culture. This did not produce 
small enough ECM fragments, as they could not be fully solubilized in 10 mg/mL 
fibrinogen despite being subjected to warming at 50 °C and thorough mixing. This 
resulted in an uneven distribution of ECM in the gels (see Fig. 3.7). In future studies, the 
ECM could be ground into significantly smaller fragments via cryomilling. 
 The idea behind pepsin digestion and mechanical grinding was to reduce the ECM 
into fragment sizes that can be solubilized into the fibrinogen solution without destroying 
binding motifs and sequestered bioactive molecules. While the duration of pepsin 
digestion was limited, further studies would likely need to verify that said proteins were 
not degraded. This could be done by a variety of methods, including performing an 
extraction method to detect soluble proteins and mass spectrometry to identify binding 
motifs, after processing and before use in culture. Alternatively, hydrogels could be 
frozen, sectioned, and subjected to IHC to detect key proteins.  
 Another potential roadblock that presented itself after gels with ECM were 





Fig. 3.7). This event obscures live and dead cells and makes an accurate count difficult to 
obtain. To circumvent this, viability could instead be measured using a colorimetric 
assay, such as the MTT and LDH assays that can be used to measure the number of live 
and dead cells, respectively80. The MTT assay measures metabolic activity and is used to 
determine cell proliferation while the LDH assay measures the rate of cell death. When 
used together and in conjunction with an initial viability count before encapsulation, 
these assays have been shown to be effective at estimating the viability of hydrogel-
encapsulated cells80. Alternatively, fibrin gels could be degraded using the serine 
protease, nattokinase, due to its fibrinolytic activity81. Leukocytes could be recovered 
from the degraded scaffolds and their viability measured by imaging. This method has 
already been used to effectively release MSCs from fibrin gels without any significant 
damage to them, and the authors of the study suggest that this approach could be utilized 
with other cell types81. 
4.5 Vascularization of hydrogels requires improved pin 
molding followed by LEC seeding and lymphangiogenesis 
Tissue engineered structures of a physiologically and clinically relevant size (~1 
mm to 10 cm), contain distances too great for effective transport of nutrients and waste 
products by diffusion82. For most tissues in the body, the maximum distance between 
cells and the vasculature is about 200 µm82. Areas in tissue engineered constructs that 
exceed this distance from the supply medium are prone to hypoxia and loss of cellular 
phenotype, function, and viability82. For these reasons, in vitro vascularization is one of 
the tissue engineering field’s greatest and most pressing challenges.  
As previously mentioned, the lymphatic vasculature and LECs that form it bring 
antigens, inflammatory cytokines, and migratory immune cells to and from the lymph 
nodes and facilitate their migration into them. LECs also support antigen presentation, 
peripheral tolerance, and lymphocyte expansion.  
Inspiration for the pin molding technique presented in this thesis comes from the 
work of Meng et al., who used it to form patent, endothelialized channels in fibrin gels 





angiogenesis with VEGF gradients, among other functional outcomes55. These gradients 
were implemented by rupturing VEGF-containing capsules with a laser, to one side of the 
endothelialized channel. Cancer cells were able to migrate through this induced network 
and into the main channel55. This approach could potentially be applied with both 
endothelial and lymphatic endothelial cells to produce vasculature of both kinds within 
the fibrin hydrogel. Some research groups have already attempted to produce blood and 
lymphatic capillaries in hydrogels. Helm et al. encapsulated blood endothelial cells 
(BECs) and LECs in fibrin-collagen gels with covalently bound VEGF and induced BEC 
and LEC angiogenesis by subjecting them to interstitial flow by use of a flow chamber63. 
While they found that BEC vessel formation was dependent on collagen content, other 
studies have achieved this without collagen. Knezevic et al. co-cultured BECs and LECs 
with adipose-derived stromal cells (ASCs) in fibrin gel supplemented with soluble 
VEGF-C64. They found that ASCs provided critical signals for blood vessel formation, 
while VEGF-C was needed for lymphangiogenesis65. Marino et al. similarly seeded LECs 
and BECs in collagen or fibrin with VEGF-A or VEGF-C and provided stromal support 
with human fibroblasts65. They found that lymphangiogenesis was dependent on 
fibroblast signaling and that both VEGF-A and VEGF-C supplementation enhanced it63. 
No significant difference was imparted by the choice of hydrogel65. Given all of these 
findings, future studies would likely need to experiment with stromal cell support and 
VEGF-A/C supplementation to achieve the best outcomes. 
A silicone mold was 3D printed to place a pin between its walls and provide a 
central chamber for the fibrin gel. Side and end chambers were also included to hold 
culture media for nutrient diffusion and humidity. The 10 mg/mL fibrinogen solution 
placed in the central chamber failed to gel within 30 minutes at 1 U/mL of thrombin 
added. Incubation times were increased to 3 hours and overnight, but full gelation still did 
not occur. Finally, the thrombin concentration was increased to 2 U/mL and the solution 
was allowed to gelate overnight. This experiment produced hydrogels that were visibly 
solidified and from which pins were removed (see Fig. 3.11). Even so, the removal of 
pins from this batch of hydrogels only resulted in one patent channel in four attempts, as 





capillary action to perfuse it through. The mechanical strength of the gel appeared 
lacking, as some of the gels separated from the silicone walls and tore as the pin was 
slowly removed. In one of the gels, this separation did not appear to occur, but the 
channel collapsed and was not perfusable. This may be due to continued gelation issues. 
Thrombin from multiple shipment batches was compared to determine if expiration or 
batch variability presented a problem, but gels made from either one of them displayed 
slow and partial gelation. It could also be that the plasma fibrinogen batch was at fault, 
but this was not tested due to time constraints. Future studies would need to ensure that 
all reagents were functional, and if the fibrin gels made from them still failed to hold their 
shape and allow channel formation, modification of hydrogels would be considered. One 
option for strengthening fibrin hydrogels is by covalently crosslinking the fibrin polymers 
with factor XIIIa, a transglutaminase that performs its function in the presence of calcium 
ions83. Fibrin polymers can be chemically crosslinked and strengthened further by 
introducing genipin, a naturally derived crosslinking molecule that displays good 
cytocompatibility84. These actions can also improve the long-term stability of fibrin 
hydrogels, alongside the addition of aprotinin, an enzymatic inhibitor that has been 
shown to slow fibrinolysis25. 
Once patent channels could be consistently formed in fibrin hydrogels, LECs and 
BECs could be introduced to endothelialize pin mold channels, as Meng et al. 
demonstrated by injecting HUVECs at the channel opening55. Channel coverage can be 
easily monitored by fluorescence imaging without sectioning or whole mount 
immunostaining, given that fluorescent protein-expressing cell lines could be acquired55. 
Vessel patency can be demonstrated by perfusing the channel with fluorescent 
microbeads and subsequent imaging55. While Meng et al. created a VEGF gradient by 
rupturing capsules to one side of the channel, a homogenous distribution of VEGF-A/C, 
supplied by incubation with media, can be used to promote vessel sprouting throughout 
the gel and form vascular networks64. While soluble VEGF was demonstrated in multiple 
studies to enable BEC and LEC vessel sprouting, immobilization of growth factors onto 
the surface of matrices by covalent binding has been shown to improve their stability and 





covalently to fibrin63. The formation of new vasculature by both BECs and LECs could 
be observed by fluorescence microscopy at multiple focal depths and assessed for vessel 
density, lumen diameter, and general morphology. 
 
4.6 Functional assays are required to show the clinical 
relevance of an integrated tissue model 
After solving the problems introduced in the previous sections of this discussion, 
namely vascularization, optimal fibrin hydrogel conditions, ECM incorporation, cytokine 
supplementation, and stromal cell support, all of these elements could be combined into a 
working model and maintained with a bioreactor system (see Fig. 4.1). Media flow could 
be facilitated by a peristaltic pump, such that the pressure difference across the system 
would drive flow through the endothelialized channels and sprouted vessels contained in 
the hydrogel. If needed, an in-line oxygenation membrane could supply additional 
oxygen to the media upstream of the chambers. Cytokines, antibodies, and migratory 
cells could be collected from the outflow chamber.  
 
 
Figure 4.1 This diagram illustrates a potential design for a vascularized fibrin hydrogel containing immune 
cell populations and supplied with culture media and antigen by tubing connected to a pump system. Gray 
background indicates fibrin hydrogel containing decellularized, processed ECM. Larger, straight lines 
indicate endothelialized pin mold channels from which fluid enters and exits the hydrogel (blue = 







 This construct could be used to perform in vitro diagnostic tests of drug 
immunoreactivity and vaccine efficacy or study the interactions of cancer cells with the 
immune system. The hydrogel scaffold and encapsulated cell populations could also be 
matured in vitro and then removed from the bioreactor for implantation to potentially 
combat lymphedema and immune deficiencies. For any of this to be plausible, it would 
first need to be validated that this model shares similar basic functionality with lymph 
nodes in the body. 
To initiate an immune reaction by the cells contained in the hydrogel, a chosen 
antigen can be introduced into the vasculature through the inflow chamber along with 
lipopolysaccharide (LPS), a bacterial endotoxin that is commonly used as an 
inflammatory stimulus86. The outflow chamber would be used to collect inflammatory 
cytokines that might be released upon later restimulation in response to immune cell 
activation. These cytokines could then be identified by use of a multiplex immunoassay. 
Giese et al. performed a similar experiment and observed the inflammatory secretion 
profile, looking at concentrations of IL-2, IL-4, IL-6, interferon gamma (IFN-γ), and 
TNF-α, among others47,87.  
Long-term viability and the development of populations of functionally relevant 
immune cell phenotypes could also be observed by degrading the fibrin matrix with 
nattokinase, collecting the cells, staining them with marker-specific, fluorochrome-
conjugated antibodies, and separating them by flow cytometry. Using a similar approach, 
Kuzin et al. identified CD3+ T cells isolated from 3D culture and grouped them by 
effector function (CD4+/CD8+) and naivety (CD45RA+/CD45RO+)86. B cells were 
identified by the CD19 marker and organized into further subtypes (naive B cells, pre-GC 
B cells, GC B cells, plasma cells, and memory B cells) by their combinations of IgD, 
CD27, and CD38 expression86. Purwada et al., on the other hand, identified GC cells by 
the surface marker GL7, and separated them into GC dark zone and light zone 
phenotypes by looking at their CXCR4 and CD83 expression levels40. Kuzin et al. also 
identified plasmacytoid and myeloid DCs by a combination of several surface markers 
and separated them from monocytes by the lack of CD14 expression86. The expansion of 





separated cell population can be assessed with a L/D stain and fluorescence microscopy. 
To understand the distribution and proliferative dynamics of cell populations within the 
matrix, the hydrogel can be removed from the bioreactor, fixed, sectioned, and stained 
with antibodies for specific surface markers. Kuzin et al. stained for CD3 and CD19 
markers to differentiate T and B cell zones, while Giese et al identified proliferating cells 
(Ki67+) and differentiated plasma cells (CD138+)86,87. Purwada et al. visualized GC 
formation by staining for GL740. 
 As a final addition to in vitro characterization, antibodies could be collected from 
the outflow chamber a few days after antigen stimulation. An enzyme-linked 
immunosorbent assay (ELISA) can be used to measure antigen-specific antibodies. It can 
also be used to observe affinity maturation as it can determine the relative affinities of 
antibodies collected at different time points to the antigen of interest88. Furthermore, as 
Kuzin et al. demonstrate, class switching can be detected by performing an ELISA in 
which antibodies against human IgM and IgG are used86. Since naive B cells can produce 
only IgM and IgD antibodies, the detection of IgG, IgA, or IgE antibodies would indicate 














 There is a need for a tissue-engineered, 3D model of a human lymph node to 
perform in vitro screening of drugs and vaccines in a more physiologically relevant 
microenvironment. While there do exist such in vitro models, they are limited in the 
extent to which they recreate the microenvironment of the lymph node. They can be 
improved by the addition of decellularized lymph node ECM, as it has the potential to 
provide encapsulated immune cells with a wide variety of highly relevant, bioactive 
peptides. Furthermore, there is a need for these tissue-engineered models to be 
implantable to deliver therapeutic cells and structure in vivo to address a variety of 
pathologies including cancer, auto-immune disease, and lymphedema. As of yet, lymph 
node models with proven functionality are not lymphatically or otherwise vascularized 
and therefore not ideally prepared for implantation and therapeutic efficacy. This problem 
can be addressed by applying a previously existing approach for vascularizing fibrin 
hydrogels by the introduction of endothelialized channels and subsequent in vitro 
angiogenesis.  
 Fibrin hydrogels were found to be a good candidate for 3D scaffolding in a lymph 
node model because they maintain high PBMC/PBC viability in culture and have been 
used in several studies as a platform for angiogenesis and lymphangiogenesis. Porcine 
lymph node tissue was successfully decellularized and shown to retain high amounts of 
collagen and laminin ECM after this process, indicating that it can be used to provide 
leukocytes with many of the binding motifs that they encounter in the lymph node 
microenvironment. However, fibronectin was not shown to be retained and further work 
could be done to ascertain which isoforms of collagen and laminin were present. Some 
immunologically relevant, soluble cytokines were detected even after decellularization of 
lymph node tissue, but these results would benefit from an expanded analyte panel and 
greater number of trials in order to get a strong sense of which important molecules are 
present and which may need to be supplemented. Further processing of the ECM is 
required to fully solubilize it for incorporation into hydrogels. The approach for 





consistent through improvements to experimental technique or hydrogel composition. At 
such a point, it would need to be determined whether endothelialization and capillary 
sprouting of BECs and LECs in response to VEGF signaling can be achieved in this 
platform. A bioreactor system is needed to support the model in vitro. Finally, functional 
assays would be required to demonstrate proliferation, the production of inflammatory 
cytokines and antigen-specific antibodies, GC formation, and the development of 
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Appendix A.1 List of all analytes included in the Luminex multiplex immunoassay and 
Bradford assay 
 
Endothelial growth factor 
Fibroblast growth factor 2 
Eotaxin 
Transforming growth factor alpha 
Granulocyte colony-stimulating factor 
FMS-like tyrosine kinase 3 ligand 




Chemokine (C-X-C motif) ligand 1 
Interleukin-10 
Chemokine (C-C motif) ligand 7 
Interleukin-12 subunit beta 

















C-X-C motif chemokine ligand 10  
Chemokine (C-C motif) ligand 2 
Chemokine (C-C motif) ligand 3 
Chemokine (C-C motif) ligand 4 
 Tumor necrosis factor alpha 
Tumor necrosis factor beta 







Appendix A.2 Full IHC IF compared to secondary-only and autofluorescence controls 
 
 
Figure A.2.1 The results of full staining, secondary-only staining, and no staining of tissue sections with 
anti-laminin antibodies. The type of tissue section is displayed on the left and the stain type on the top of 
the image. All scale bars = 500 μm. 
 
Figure A.2.2 The results of full staining, secondary-only staining, and no staining of tissue sections with 
anti-fibronectin antibodies. The type of tissue section is displayed on the left and the stain type on the top 
of the image. All scale bars = 500 μm. 
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The lymphoid system protects the body from pathogens through organs that 
produce immune cells and facilitate immune surveillance. The study and treatment of a 
variety of pathologies affecting or interacting with the immune system can benefit from 
tissue engineering strategies. These designs can be implemented in vitro and in vivo 
through a variety of fabrication methods. Here we describe structure, cell types, and 
signaling found in the bone marrow niche, thymus, peripheral lymphoid organs, and 
lymphatic vasculature. We then summarize lymphoid tissue engineering studies from 
recent reports, and choice of design components including scaffolds, stromal cells, and 
chemical or physical signals. Finally, we discuss the current limitations and future of this 
field. 
 








The purpose of the immune system is to defend the body from pathogens while 
maintaining tolerance of the body’s own tissues and avoiding adverse reactions to non-
pathogenic external sources of antigens (i.e. commensal bacteria, food, etc.). The 
requisite functions for the achievement of this purpose are divided between different 
subsets of immune organs. The primary lymphoid organs, namely the thymus and bone 
marrow, are the sites for production and differentiation of hematopoietic progenitors into 
lymphoid and myeloid cells which provide the adaptive and innate branches of the 
immune response. They also provide an environment conducive to the selection of the 
aforementioned lymphocytes which are functional yet do not display pathogenic 
autoreactivity. The secondary lymphoid organ subsystem is comprised of the spleen, 
lymph nodes, tonsils, Peyer’s patches, adenoids, and other lymphoid formations, which 
are found in a variety of tissues and referred to as the mucosa-associated lymphoid 
tissues1. These organs survey the body (primarily through the lymphatics) for antigens 
and are responsible for mounting an adaptive immune response by selectively activating 
B and T cells whose receptors are specific to the threat. Alternate forms of the  antigen-
specific receptors on B cells are secreted as antibodies. Tertiary lymphoid organs form in 
tissues experiencing chronic inflammation, and perform many of the same functions as 
secondary lymphoid organs. Finally, the lymphatic vasculature, although not placed in 
any of these three categories, plays a vital role in the transportation of immune cells and 
pathogens. In addition, the lymphatic endothelial cells of the vasculature support 
secondary lymphoid organs by enabling immune cell chemotaxis and antigen 
presentation2. Within the lymphatic organs, lymphocytes are supported by a variety of 
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stromal cells that provide them with signals needed for survival, growth, development, 
and migration.  
The design of biomimetic constructs or models, grounded in an understanding of 
biology and engineering principles, has made significant contributions to the field of 
regenerative medicine and resulted in a supply of commercially available products that 
are used to develop approaches to replace injured or dysfunctional tissues. This endeavor, 
known as tissue engineering, makes use of cells, scaffolds, and a variety of chemical or 
physical signals to replicate the structure and function of natural tissues [Figure 1]. For 
the purposes of immune tolerance, it is often most efficacious to use autologous cells 
from the intended recipient of a tissue engineered construct3. These cells may be taken 
from a patient to be expanded and seeded in a scaffold ex vivo or they may simply be 
recruited to a site of implantation of a scaffold to be incorporated into a design in vivo. 
Stem cells are another useful resource since they are self-renewing and capable of 
differentiation. The term scaffold refers to a variety of three-dimensional structures, often 
hydrogels, which can be used to contain and provide signals to cells. These may be 
derived from natural materials or from synthetic sources and generally have pores or 
channels that allow the movement and interaction of one or more cell types within the 
construct. It is imperative that these materials not be cytotoxic and that, if they are 
intended to be implanted, display full compatibility with the recipient animal model or 
human patient. Signals that are used in tissue engineered designs may include chemical 
signals such as growth factors, cell adhesion peptides, chemokines, and other relevant 
molecules that promote viability, proliferation, migration, or specific functions of a target 
cell population. Physical signals may be provided by the material used for scaffolding, as 
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is the case for factors such as stiffness or surface topography. External physical signals 
such as fluid flow, tensile or compressive loading, and even electrical stimulation can 
play an important role in the development of an intended cellular phenotype or function.  
 
Fig. 1. Tissue engineering design often utilizes a combination of scaffold materials, cell types, and 
environmental signals to replicate natural function and achieve desired outcomes. Reproduction of the 
artwork: “Ligand”, “Receptor”, “Lymphocyte”, and “Collagen” by Servier Medical Art at 
https://smart.servier.com/ is permitted under the terms of the Creative Commons Attribution Unported 3.0 
license. 
 
 The design of a tissue engineered construct generally falls into one of a set of 
distinct approaches. One standard approach involves the seeding of cells into a porous 
scaffold. Such a design may be constructed by the casting or bioprinting of a polymeric 
material or hydrogel. Bioprinting provides a means of creating a complex spatial 
organization that may not be possible with simpler methods but requires the use of 
materials whose properties allow them to be effectively printed4. When stem cells are 
placed in 3D clusters that self-organize and differentiate into requisite somatic cell types, 
it is known as organoid formation5. The latter approach is often supported by placement 
of the cells within a scaffold material but it is also possible for these cells to secrete their 
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own extracellular matrix. In order to provide cells within a tissue engineered construct 
that is maintained in vitro with nutrients and waste removal, scaffolds are often placed 
within a perfused housing known as a bioreactor. Bioreactors can also be used to provide 
chemical or physical signals with or without temporal variation. Alternatively, a construct 
can be implanted into an animal model for in vivo maturation or designed to simply exert 
its effect directly upon implantation within a patient, as is the case with many injectable 
scaffold approaches. Advances in microfluidic technology have led to its combination 
with 3D cell culture to create organ-on-a-chip models. An advantage of this approach is 
the high degree of control over architecture and perfusion that it imparts6. Another 
technology, which permits use of the body’s own structural design, is decellularization: 
removal of cellular content from an organ or tissue leaving behind the natural scaffold 
provided by its extracellular matrix. In addition to consideration of the scaffold type and 
method used, the material itself is an important factor. Many synthetic materials are 
easily and consistently producible and can be modified with natural peptides or other 
bioactive molecules to impart biological function. These modifications can be forgone if 
a naturally derived material is chosen but these are generally more expensive, harder to 
manipulate and process, and can be more vulnerable to batch variability.  
Lymphatic bioengineering involves the use of cells and biological factors in an 
appropriate medium or scaffold to reconstruct or mimic the function of some part of the 
lymphoid organ system. This endeavor has the potential to provide the medical sector 
with a variety of services. For example, it could better establish the efficacy and safety of 
pharmaceutical drugs that can be limited by their interaction with the immune system and 
the resultant, potentially immunotoxic, response. The advent of highly biomimetic, three-
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dimensional engineered models of each organ of the immune system could provide the 
industry with a reliable, reproducible, cost-effective, and ethical alternative to the pre-
clinical trials which are performed on animal models and whose results often translate 
poorly to the clinical phase6,7,8. Some other experimentally-related concerns with the use 
of animal models include the presence of fundamental differences in the immune systems 
of different species and the inability to fully measure or control the complex cellular 
interactions in a test subject5,6. Additionally, in vitro models provide a multitude of 
experimental benefits including the ability to manipulate signaling pathways, engineer 
tissue niches, and introduce epigenetic or genomic alterations to cell lines9. Of these, the 
ability to recreate the appropriate, 3-dimensional tissue niche in terms of extracellular 
matrix components, chemical gradients, scaffold stiffness, and other mechanical gradients 
is especially vital for immune cell function, giving a bioengineered tissue model an 
advantage over oversimplified, 2-dimensional culture systems6,9. Furthermore, in vitro 
models provide an improved system for imaging or performing molecular analyses at 
multiple timepoints in an experiment, thereby allowing observation of temporal 
dynamics5,10. Finally, bioengineered models have the potential to encapsulate individual 
specificity within therapeutic screening tests by isolating, expanding, and seeding the 
patient’s own cells in the scaffold or construct. This could serve to capture the traits of 
their specific disease by using affected cell populations, avoid adverse immune responses 
to allogeneic cells, and characterize their personalized reaction to a drug or 
immunotherapy6,8,11. 
Alongside providing in vitro systems for drug and immunotherapy screening, 
bioengineered lymphatic tissue models can provide a means of studying the dynamics of 
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auto-immune disease and cancer within lymphoid organ-specific microenvironments7,12. 
This could elucidate the evolution of these pathologies and give insight on potential 
immunotherapeutic approaches based on the interactions of diseased cells with 
surrounding immune cells. Furthermore, the recreation of tissue-specific niches involving 
hematopoietic stem and progenitor cells may allow observations of lineage development 
and the expansion of rare, potentially therapeutic cell populations9,13. 
Another beneficial outcome of the progression of lymphatic tissue engineering 
would be the implantation of secondary lymphoid organ constructs to replace or bolster 
inadequate natural immune function. Such an approach could be used as a vehicle for 
immunotherapy by implanting immune cells in a physiologically and pathologically 
relevant location. These cells could be pre-primed against an antigen particular to the 
infectious disease vector or to the cancer type of interest. They can also be provided with 
the appropriate microenvironment by the scaffold they are seeded in, allowing in vivo 
expansion and improved viability. Furthermore, this tactic could be used to combat 
pathological inflammation and auto-immune disease by providing a population of 
regulatory immune cells to control these adverse immune responses11. Additionally, the 
negative effects of genetic disorders involving an inhibition of lymphatic organ 
development or lack of function such as DiGeorge syndrome, severe combined immune 
deficiencies (SCID) or Fanconi anemia could be circumvented by implantation of an 
appropriate lymphatic tissue construct to restore function. As a final application, the 
implantation of a tissue-engineered secondary lymphoid organ construct (alongside 
engineered lymphatic vasculature, as needed) could be used as a direct tissue replacement 
to treat inherited or acquired lymphedema, the accumulation of interstitial fluid resulting 
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from insufficient lymphatic drainage. Acquired lymphedema is often a result of radiation 
therapy or tumor removal14. An additional benefit of such a replacement would be the 
restoration of immune surveillance provided by the lost lymphatic organs and 
vasculature. 
 
Engineering the Bone Marrow Niche 
 
The bone marrow is the primary home of the hematopoietic stem cell (HSC) that 
has the potential for both self-renewal and differentiation into the immune cells of the 
myeloid and lymphoid lineages. Regulation of HSCs in the bone marrow is dependent on 
the signaling dynamics of local tissue microenvironments called niches [Figure 2]. There 
are two distinct HSC niches; those of the first type (the vascular niche) are localized 
around sinusoid vessels, near endothelial cells11. A second type (the endosteal niche) 
exists within the endosteum, in the presence of osteoblasts11. The first supports expansion 
and differentiation whereas the second maintains a reservoir of long-term progenitors in a 
quiescent state11. The maintenance of these niches is influenced directly and indirectly by 
several local cell types including endothelial cells, mesenchymal and perivascular stromal 
cells, osteoblasts, osteoclasts, macrophages, and cells of the sympathetic nervous 
system15. Furthermore, a number of extracellular matrix proteins contribute to the 
structure and function of the niche, including fibronectin, tenascin, thrombospondin, 
elastin, laminin, collagen, and a variety of proteoglycans16. Finally, the hematopoietic 
niche is hypoxic, an attribute that may promote local signaling, which contributes to the 





Fig. 2. The bone marrow stem cell niche contains stromal cells and provides a variety of signals to resident 
HSPCs. Adapted from Zhang et al., 201918. Reproduction is permitted under the terms of the Creative 
Commons Attribution 4.0 International license. 
 
 The ability to recreate the bone marrow niche in vitro opens the door to improved 
expansion of hematopoietic stem and progenitor cell (HSPC) populations that are 
valuable for treating a variety of hematological disorders in which blood cell presence or 
function is lost19. It also provides a platform for ex vivo drug screening and for the study 
of hematopoietic biology and lineage commitment20. Furthermore, it can be used to 
promote the commitment of hematopoietic progenitors to a lymphoid lineage to produce 
B or T cells that combat infection and provide a means of suppressing the initiation and 
development of cancer21,22. 
 Given the complexity of the bone marrow niche, the challenge of tissue 
engineering a model to recreate its functions includes choosing an appropriate set of cell 
types in a sufficiently biomimetic scaffold to provide necessary chemical, mechanical, 
and physical-spatial cues. This has been attempted by several different research groups, 
generally by seeding HSPCs within a 3D scaffold of natural or synthetic polymers 
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alongside a supportive stromal cell population. While early studies simply provided an 
undefined stromal population from bone marrow cell cultures, more recent studies have 
used mesenchymal stromal cells isolated from the bone marrow, placenta, or cord blood. 
Furthermore, a 2019 study by Braham et al. included mesenchymal stem/stromal cells 
(MSCs) committed toward an osteogenic or adipogenic lineage as well as endothelial 
progenitor cells with the rationale that adipocytes and endothelial cells are key stromal 
cells in the hematopoietic niche17. The use of multiple stromal cell types to better recreate 
the bone marrow niche may gain popularity going forward.  
The scaffold-with-stromal-cell approach often requires the inclusion of additional 
soluble, chemical signals, which indicates that a sufficiently biomimetic cellular and 
structural design has not yet been developed to induce the full portfolio of chemical 
signaling found in the niche. Common supplementary cytokines to encourage the 
maintenance and proliferation of HSPCs in these tissue-engineered scaffolds include stem 
cell factor, Fms-like tyrosine kinase 3 ligand, thrombopoietin, and various interleukins. 
Furthermore, the choice of a synthetic polymer-based scaffold often requires 
modifications with natural molecules to promote cell adhesion and viability but can 
provide greater control over its mechanical properties. Another, different method to 
provide a scaffold construct with cells and chemical signals is to incubate it in vivo. An 
example of this strategy is given by a study by Torisawa et al. in which a microfluidic 
chip combined with a collagen and demineralized bone powder scaffold containing pro-
osteogenic factors was seeded in vivo by cells recruited after implantation within a 
murine host20. A summary of experimental designs and key results are presented in 





Fig. 3. Experimental setups and key results for a selection of bone marrow niche engineering studies. A i) 
A perfused silk sponge functionalized with fibronectin is ii) seeded with megakaryocytes (green = cells, 
blue = silk, scale bar = 100 μm) and iii) forms and releases platelets (scale bar = 50 μm). B Flow dynamics 
contribute to HSPC culture in a bioreactor with a perfused hydrogel. C HSPCs are perfused into a collagen-
based microvessel platform to study migration and stromal cell interactions. HSPC adherence is influenced 
by stromal cell interactions. Panel A is adapted from Di Buduo et al.23, B from Rödling et al.24, C from 
Kotha et al.25. Panel A figures are reprinted with permission from Elsevier. Reproduction of the figures in B 
and C is permitted under the terms of the Creative Commons Attribution 4.0 International license. 
 
Other design aspects that have been explored within the last decade include the 
use of active perfusion to supply nutrients and provide physiologically mimetic, 
supportive mechanical signals from fluid flow while removing waste26. Perfusion can be 
achieved within the context of a microfluidic device, also known as the bone-marrow-on-
a-chip approach, or within a larger scale bioreactor. While microfluidic devices provide 
high throughput and precise control, the limitation on the volume of the system may 
restrict its complexity which, in the case of attempting to replicate the bone marrow 
niche, has been seen by some as a drawback26. Additionally, a number of studies have 
characterized hypoxic conditions within their constructs and found this state able to 
improve the viability and proliferation of the seeded cells while promoting gene 
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expression characteristic of the hypoxic bone marrow niche17,27,28. Brief descriptions of 
bone marrow niche engineering studies from various research groups are given in Table 
1, below. 
 
Table 1. Recent approaches to engineering the bone marrow niche for the expansion of HSPCs 
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Engineering the Thymus 
 
The thymus is the site of T cell maturation. Lymphocyte progenitor cells from the 
bone marrow are recruited to the thymus by homing signals and there encounter a tissue-
specific niche which promotes their differentiation into mature T cells35. The thymus 
contains two distinct regions, the cortex and the medulla [Figure 4]. Each one contains its 
own specific type of thymic epithelial cells (TECs) that provide essential trophic signals 
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alongside other stromal cell types, which include mesenchymal fibroblasts, macrophages, 
and dendritic cells (DCs)36,37. In particular, Notch ligand signaling provided by TECs is 
crucial for T cell development38. Furthermore, they provide the signals necessary for 
positive and negative selection of thymocytes, which occur in the cortex and medulla, 
respectively37. These stages of development result in a population of mature T cells with 
potent yet non-autoreactive T cell receptors. The three-dimensional organization of TECs 
in the thymus is a requirement for their function; monolayer culture of these cells results 






Fig. 4. The thymus is divided into two main areas, the medulla and cortex, and is responsible for the 
production of mature T cells and maintenance of central tolerance. Adapted from Singh et al., 201739. 
Reprinted with permission from Elsevier. 
 
 
 The thymus is particularly susceptible to the loss of its TEC population and a 
subsequent deficiency in T cell production, which compromises the immune system35. 
This organ naturally degenerates over the course of the human lifetime, with peak 
cellularity and function occurring around nine months after birth and decreasing with 
age37. An additional concern that could be addressed by thymic tissue engineering is the 
existence of genetic defects that result in diseases such as Di George syndrome in which 
the thymus fails to develop and there is an innate lack of T cell production38. External 
insults that can compromise the function of the thymus include atrophy through acute 
infection, chemotherapy, and therapeutic irradiation37. These problems can potentially be 
solved by in vitro production and subsequent administration to the patient of therapeutic 
Reproduction rights pending. See 
Singh, 2017 Fig. 2.A (upper portion)39. 
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cell populations (TECs and/or mature T cells) or by the implantation of a functional, 
tissue engineered thymic graft. Additionally, central immune tolerance to allografts could 
be induced for donor-specific tissues by use of a thymic construct35. 
 The thymic niche is similar to that found in the bone marrow in the sense that its 
complexity is imparted by 3D stromal cell organization, signaling, and extracellular 
matrix (ECM) components that provide physical anchors and harbor chemical factors. 
However, this niche is less well understood and fewer attempts have been made to 
determine what combination of scaffold, stromal cells, and cytokines are minimally 
necessary for an effectively biomimetic model. Commonly used exogenous factors to 
promote T cell production include Flt-3 ligand, SCF, and IL-7. A study by Poznansky et 
al. attempted this goal by seeding HSPCs and a mixture of thymic stromal cells (TSCs) 
into a 3D synthetic scaffold, resulting in a greater proliferation of mature T cells than in a 
simple co-culture40. Other traditional, scaffold-using studies include a study in which 
Matrigel® and thymic tissue were placed in a silicone construct, and a study in which 
PCL and collagen were used to provide a hybrid matrix for HSPCs and supportive 
stromal cells36,41. In both of these cases, however, in vivo maturation was required for the 
desired T cell production, indicating that a sufficiently biomimetic scaffold model 
remains to be constructed in vitro. Most recent approaches instead utilize organoid 
formation or a decellularized thymus matrix and many of them use implantation to 
achieve maturation and T cell production in vivo. Organoid formation has been 
approached by combining HSPCs with medullary TECs and thymic mesenchyme on a 
gelfoam base38. A simplification of this stromal cell population requirement was achieved 
by Seet et al. through the use of a DLL1-transduced stromal cell line to form organoids 
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with a mature T cell production. Another advantage of the aforementioned design is its 
ability to obtain this result in vitro and without exogenous growth factors42.  
Decellularization of the thymus for use in tissue engineering has gained recent 
popularity. This approach was demonstrated by Fan et al. Decellularized thymic ECM 
was reseeded with TSCs and HSPCs, provided with exogenous IL-7, and used to produce 
mature T cells in vitro35. Another research group augmented this approach by first 
incubating TECs in a composite hydrogel with growth factor and stromal cell support, 
seeding the decellularized thymus with these and other stromal cells, and finally 
implanting the construct to produce mature T cells in vivo43. A summary of experimental 
designs and key results are presented in Figure 5, below. Brief descriptions of thymus 







Fig. 5. Experimental setups and key results for a selection of thymus engineering studies. A i) Amphiphilic 
peptides and adaptor complexes modified with antibodies form self-assembling hydrogels with embedded 
TECs. These gels ii) maintain TEC viability (green = live, red = dead) and iii) support T cell production 
when implanted in B6.nude mice. B Decellularized thymic scaffolds were reseeded with TECs and 
implanted in the kidney capsule of athymic nude mice (scale bar = 100 μm). This approach was compared 
to reaggregation thymic organ culture in its ability to produce T cells upon engraftment. Panel A figures are 
adapted from Tajima et al.37 and B from Hun et al.43 . Reprinted with permission from Elsevier. 
 
Table 2. Recent approaches to engineering the thymus to produce mature T cells from HSPCs 































































































































































Engineering the Peripheral Lymphoid Organs 
 
 The peripheral lymphoid system includes the spleen and lymph nodes as well as 
other mucosa-associated lymphoid tissues, such as the tonsils and Peyer’s patches, which 
are distributed throughout the body46. The purpose of these organs and tissues is to 
enhance immune surveillance by filtering extracellular fluids, provide an environment for 
effective antigen capture and presentation, and facilitate adaptive immune responses46. 
Extracellular fluid called lymph drains from tissue and flows into the lymph nodes via 
afferent lymphatic vessels and brings with it antigens produced by infection or 
malignancy46 [Figure 6]. Furthermore, antigen-bearing dendritic cells are actively 
recruited to the lymph nodes by chemokine gradients46. B and T lymphocytes are present 
in designated, separate areas in the lymph node46. The architecture of the lymph node 
promotes the exposure of naive T cells to antigen-presenting macrophages and dendritic 
cells46. Upon activation, T cells migrate to the edges of their zones to encounter B cells 
and provide helper signals46. Activated lymphocytes proliferate and differentiate in the 
lymph node and leave via the efferent vessels to perform their effector functions. 
Leukocytes in the paracortex (T cell zone) of the node are surrounded by stroma referred 
to as reticular meshwork that is composed of fibroblastic reticular cells and the 
extracellular matrix fibers (also known as reticular fibers) that they secrete47. This 
meshwork enables lymphocyte migration and forms conduits for the transportation of 
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soluble antigen and inflammatory cytokines. In the lymph node, B cell zones are home to 
the germinal center (GC) reaction, a key process that results in B cell antibody class 
switching and affinity maturation48 [Figure 6, upper right].  
The white pulp of the spleen carries out a similar function to the lymph nodes but 
does so with bloodborne antigens rather than those collected by the lymph. Akin to the 
lymph nodes, the spleen has designated B and T cell zones, populations of antigen 
presenting cells, and the capacity for germinal center formation49. In addition to those 
carried in the blood and lymph, antigen is able to contact the lymphatic system through 
mucosal surfaces in the gastrointestinal and respiratory tracts. They are collected by 
microfold cells, specialized epithelial cells which are present in a variety of mucosa-
associated lymphoid tissues50. All of the aforementioned peripheral lymphoid organs and 
tissues share a similar basic organization that allows them to collect antigen and have it 
presented to circulating lymphocytes. These secondary structures are inherently dynamic. 





 Fig. 6. The lymph nodes facilitate interactions between stromal cells and lymphocytes which allow 
activation and the progression of the adaptive immune response. Adapted from Nosenko et al.11. 
Reproduction is permitted under the terms of the Creative Commons Attribution 4.0 International license. 
 
 The loss of lymph nodes to radiation therapy or surgical resection can result in 
lymphedema and susceptibility to infection or further malignancy52. The construction of 
functional peripheral lymphoid organ models could replace lost function and treat 
lymphedema under these conditions. Besides tissue replacement, these models could also 
be used in vitro to test the immunogenicity of pharmaceutical drugs, develop vaccines in 
preclinical stages, and generate highly specific plasma cells for adoptive 
immunotherapy53,54,55. 
 Many of the peripheral lymphoid organ tissue-engineering studies of the last two 
decades were focused on either the production of a germinal center reaction (using only B 
cells) or on the formation of more efficient immunological synapses (T cells and APCs) 
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in 3D. Of the former, studies by Purwada et al. show promising results. In the first of 
these publications, a gelatin and silicate nanoparticle hydrogel was used to incubate B 
cells in the presence of a transgenic stromal cell line and exogenous IL-456. The stromal 
cells in this study produced CD40L and BAFF to replicate the function of the T follicular 
helper (TFH) cells and follicular dendritic cells (FDCs) found naturally in the lymph 
node. The latter study replaced the modified gelatin matrix with a PEG-maleimide 
scaffold conjugated with adhesion peptides and was able to achieve GC-like B cell 
phenotypes, antibody class switching, and the production of antigen-specific B cells54.  
With regard to those studies focused on the formation of immunological synapses 
and T cell activation, microfluidic devices provide a highly controllable format with 
which to study specific behaviors, as demonstrated by Rosa et al. in a study that looked at 
T cell and DC interactions under controlled flow conditions57. The use of artificial APCs 
for the activation of T cells in 3D culture conditions has been recently investigated by 
research groups out of Barcelona and Harvard and found to have an advantage over 
traditional 2D culture approaches58,59. The study by Cheung et al. found success in the 
complementary use of soluble mitogenic signals and liposome membrane-bound T cell 
receptor (TCR) stimulation ligands co-delivered by matrix-forming silica microrods to 
achieve rapid expansion of T cells59. Finally, injectable gels have proven their use in the 
delivery and expansion of T cells in vivo. This was accomplished using an alginate gel 
functionalized with GFOGER peptide, and through a polyisocyanopeptide hydrogel 
functionalized with GRGDS60,61. This approach can be applied to the immunotherapeutic 
treatment of cancer by delivering and expanding T cells that can recognize tumor-specific 
antigens at the location of a tumor or tumor resection site60. These studies included an 
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integrin-binding peptide to enable cell migration and egress from the gel into the site of 
interest60,61.  
Of the studies that involve both T and B lymphocytes, long term research by 
Giese et al. has resulted in a bioreactor with RGD-Dextran gel discs that is able to 
support a lymphocytic immune response to protein aggregates, and maintain separated T 
and B cell zones, mimicking secondary lymphoid organ structure53. While this series of 
publications focused on in vitro functionality, other studies implemented in vivo 
recruitment of immune cells to seed implanted collagen sponges supported by thymus-
derived stromal cells62,63. These efforts resulted in the induction of distinct B and T cell 
areas, antigen-specific antibody production, and even some evidence of a secondary 
immune response upon further stimulation. There have also been recent attempts to 
utilize decellularized lymph nodes as a scaffold for the in vivo production of potentially 
therapeutic cell populations. One example is the work of Lin et al. demonstrating the use 
of this approach to produce anti-tumor DCs in a biologically relevant 
microenvironment52. A summary of experimental designs and key results are presented in 
Figure 7, below. Brief descriptions of peripheral lymphoid organ engineering studies 






Fig. 7. Experimental setups and key results for a selection of peripheral lymphoid organ engineering 
studies. A (upper panel) A bioreactor that is supplied with cell media and oxygen contains a hydrogel 
matrix seeded with lymphocytes and stromal cells. (lower panel) Inflammatory cytokines are secreted in 
response to specific antigen challenges. B Crosslinked Gelatin-SiNP hydrogels containing naïve B cells and 
engineered stromal cells produce GC B cells (scale bar = 10 mm). Panel A figures are adapted from Giese 
et al.64 and B from Purwada et al.56. Reprinted with permission from Elsevier. 
 
Table 3. Recent approaches to engineering the peripheral lymphoid organs to mount an adaptive immune 
response to antigen challenge 
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Engineering the Lymphatic Vasculature 
 
 Recent studies of the functions of lymphatic vessels and the expression profiles of 
lymphatic endothelial cells (LECs) have uncovered a rich and dynamic role for this 
component of the lymphatic system. Lymphatic vessels spread out into the skin and 
mucosal membranes, draining lymph from tissues that contain sufficient interstitial 
fluid74. The LECs surrounding the lymphatic capillaries form discontinuous cell 
junctions, which can respond to changes in interstitial pressure to allow fluid entry via 
specialized valves74. Lymphatic vessels contain intraluminal valves to maintain 
unidirectional flow of the lymph; the contraction of smooth muscle surrounding the 
vessels also serves this purpose74[Figure 8]. A 2019 study by Berendam et al. revealed 
that LECs have different expression profiles than blood endothelial cells for proteins 
influencing extracellular matrix production, cell adhesion, and chemotaxis75. 
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Furthermore, the expression profiles of lymph node LECs vary from those of LECs in 
other tissues75. CCL21 is produced by LECs to recruit DCs and promote directional 
crawling74. Additionally, the CCL21 gradient produced by subcapsular sinus LECs 
enables migration of DCs into the lymph node paracortex to interact with T cells74. 
Inflammation causes the expression of VCAM-1 on LECs, which promotes T cell and 
DC entry into lymphatic vessels while sphingosine-1-phosphate (S1P) plays an important 
role in T cell migration and survival in the lymph node74. Furthermore, lymph node LECs 
produce IL-7, which supports lymphocyte expansion during lymph node remodeling74.  
In addition to functions that support an immune response, LN LECs have an 
immunomodulatory role. These cells produce a variety of TGF-β superfamily proteins, 
which have immunosuppressive effects75. Lymph node LECs can also directly express 
self-antigen to maintain peripheral tolerance via CD8 T cell deletion or transfer it to DCs 
that use it to cause CD4 T cell anergy through MHC-II presentation75. A final function of 
the lymphatic vasculature, which is not directly related to immune activity, is the 
transport of dietary lipids from the gut76. Lymphatic vessels in the villi called lacteals are 






 Fig. 8. The lymphatic vasculature drains interstitial fluid from the tissues, enabling the transport of 
antigen and immune cells to the peripheral lymphoid organs. Adapted from Jiang et al., 201977. 
Reproduction is permitted under the terms of the Creative Commons Attribution 4.0 International license. 
 
 There are several motivations for the development of tissue engineered lymphatic 
vasculature. Lymphedema is a symptom of congenital or acquired lymphatic impairment; 
the second form is often a result of radiotherapy or surgery for the treatment of 
cancer78,79. Reconstruction of the lymphatic vasculature using tissue engineered 
constructs can alleviate lymphedema and provide an advantage over traditional surgical 
repair or lymph node engraftment, two current solutions that have yielded limited 
success79,80. Furthermore, skin grafts and other tissues or organs intended for 
transplantation can benefit from inclusion of lymphatic vasculature through the provision 
of lymphatic drainage and immune accessibility81,82. Finally, in vitro models of the 
lymphatic vasculature can provide a means of studying the functions of LECs with 
regards to fluid flow, immune cell interactions, or the transport of dietary lipids76,83.  
 A look at studies attempting to tissue-engineer lymphatic vessels reveals a variety 
of approaches. Some of the earliest efforts were pioneered by Swartz and colleagues; 
these feature collagen or fibrin gels set in a perfused bioreactor alongside blood 
endothelial cells83,84. Their study used a collagen and fibrin combination gel modified 
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with a vascular endothelial growth factor (VEGF) fusion protein bound to the fibrin 
component84. This approach resulted in the in vitro formation of lymphatic capillaries and 
was used to study the effect of fluid flow and shear stress on LEC morphology83,84. A 
later study took a different direction with the creation of a LEC-enterocyte transwell 
interface model to study the transport of lipids from the gut to the lymphatics76. Dai et al. 
studied an in vivo approach, forming a polyglycolic acid (PGA) scaffold seeded with 
LECs in a silicone tube for implantation and maturation of a lymphatic vessel in a murine 
model80. A number of growth factors including VEGF were used to support this design 
during an initial in vitro incubation phase80. Marino et al. returned to the use of fibrin and 
collagen, supplemented with VEGF-A and VEGF-C to form blood and lymphatic 
capillaries both in vitro and within an implanted skin graft model81. Fibroblasts acted as 
supportive stromal cells, and keratinocytes formed an integral part of the skin model in 
this study81. Another publication revealed that lymphatic vasculature can be formed 
without an exogenous scaffold as fibroblasts can produce ECM and form vessels when 
cultured with LECs78. The authors also showed that similar results can be achieved in a 
collagen gel and that hepatocyte growth factor (HGF) and VEGF-C promote 
lymphangiogenesis. Hadamitzky et al. attempted a similar strategy using a natural matrix, 
seeding LECs within a nanofibrillar collagen scaffold with conjugated VEGF-C79. 
Implantation in a porcine model led to promising histological results and an improvement 
in bioimpedance readings, indicating interstitial fluid drainage. Most recently, Knezevic 
et al. used adipose-derived stromal cells to support the development of lymphatic 
vasculature in vitro, supported by a fibrin hydrogel82. The use of these stromal cells had a 
positive impact on LEC migration and proliferation, resulting in better vasculogenesis. A 
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summary of experimental designs and key results are presented in Figure 9, below. Brief 






Fig. 9.  Experimental setups and key results for a selection of lymphatic vessel engineering studies. A PGA 
sheets containing LECs are wrapped around silicone tubes and form lymphatic vessels after implantation in 
nude mice for 6 weeks. B Stacked sheets of fibroblasts and LECs form vascular networks (scale bar = 5 
mm). When LECs are layered between collagen gels, the degree of tube formation is dependent on HGF 
and VEGF-C. Panel A figures are adapted from Dai et al.80 and B from Gibot et al.78. Reprinted with 
permission from Elsevier. 
 
 
Table 4. Recent approaches to engineering lymphatic vessels 
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Summary, Challenges, and Future Directions 
 
 The field of lymphoid tissue engineering has seen notable accomplishments over 
the last few decades. Bone marrow niche models have been used to expand HSPC 
populations and guide their differentiation into a variety of lineages. These studies have 
also recreated other facets of the niche including hypoxia and stromal cell matrix 
deposition. Furthermore, the human blood compartment has been reconstituted in 
depleted murine models. Thymic constructs have produced mature T cells from HSPCs 
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and restored thymic T cell production in animal models. Tissue-engineered constructs 
mimicking some functions of peripheral lymphoid organs have shown an improvement 
over 2D cell culture with respect to T cell expansion and activation. They have also 
achieved germinal center reactions, resulting in high affinity, class-switched antibody 
production. Additionally, DC and T cell migration and interactions have been studied 
closely through microfluidic devices partially recreating the environment of these tissues. 
Finally, attempts to engineer lymphatic vasculature have achieved a degree of 
lymphangiogenesis in vitro and vessels that display natural function in vivo.  
 There are a number of visible trends in recent studies of lymphoid tissue 
engineering. Decellularization has become a popular method for producing highly 
biomimetic natural scaffolds that allow reseeding and delivery of cells. This approach has 
been implemented for lymphoid organs whose structures lend themselves to effective 
decellularization, namely the thymus and lymph nodes. Current bone marrow models use 
MSCs for stromal support and in many cases are still dependent on a set of exogenous 
cytokines although recreation of the niche has also been achieved without these. 
Continuing to ascertain what subsets of stromal cells best support the bone marrow niche 
will likely be advantageous for advances to these models. Thymic constructs are likewise 
dependent on support by TECs, although a recent study by Seet et al. used a custom 
stromal line instead of primary stromal cells that require extra costs associated with 
isolation, are susceptible to experimental variability, and may be limited by supply 42. 
These cells may be engineered to express specific cytokines needed for the 
microenvironment. With regards to the engineering of peripheral lymphoid tissues, T cell 
activation designs have benefited from the use of silica microparticles. These can be 
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coated with lipids for functionalization with activation ligands, carry soluble cytokines, 
and even self-assemble into 3D structures. Several studies that have implemented 
hydrogel scaffolds not containing natural cell adhesion peptide sequences have 
functionalized their matrices with said ligands since integrin binding provides a key 
mechanism for lymphocyte migration. Attempts to create lymphatic vasculature mostly 
utilize natural hydrogels such as collagen or fibrin as a scaffold, fibroblasts or adipose 
stem cells (ASCs) as supportive stromal cells, and incorporate VEGF-C either as a bound 
or soluble signal. Little has been done to demonstrate the clinically relevant, functional 
potential of these vessels although a study by Hadamitzky measured the effect of their 
implanted construct on bioimpedance in a porcine lymphedema model79.  
 There are many challenges and unanswered questions that present themselves to 
those seeking to advance the field. The bone marrow niche has been shown to contain 
stiffness gradients and complex ECM patterning that may affect resident cell behavior85. 
Although methods for the mechanical characterization of tissue-engineered constructs 
exist, little has been done in the field of lymphatic engineering to explore these 
properties. Furthermore, attempts at engineering the niche have been primarily focused 
on the expansion of HSPCs for the purpose of producing lymphocyte populations, which 
have readily apparent clinical uses. However, there may also be reasons to use such a 
platform for the production of innate immune cell populations. One such reason may be 
the production of anti-inflammatory or “M2” macrophage subtypes, which promote 
wound healing and support the incorporation of implanted lymphatic constructs86. 
Microfluidic platforms have been used to directly observe immune cell migration and 
interactions in the context of bone marrow and peripheral lymphoid organ models. As of 
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yet, this approach has not been applied to thymic models and has the potential to 
elucidate key behaviors of the immune and stromal cells in this organ.  
Attempts to engineer a germinal center in peripheral lymphoid organ constructs 
have not yet demonstrated formation of dark and light zones, two distinct germinal center 
areas that are regulated by the expression of chemokine receptors on their resident B cells 
and may contribute significantly to efficient affinity maturation48. Furthermore, although 
high affinity antibodies have been generated for hapten antigens in these models, their 
ability to generate antibodies for more complex antigens has not yet been tested.  
Tissue engineered models of the lymphatic vasculature have focused primarily on 
the use of VEGF-C to promote vessel sprouting but full development of mature vessels 
may depend on other chemical factors such as Notch ligands87. Furthermore, the design 
of VEGF-C gradients, instead of a more homogeneous inclusion seen in recent studies 
would be more biomimetic and may contribute to improved development of the 
vasculature87,88. It may also be beneficial to implement and characterize smooth muscle 
cell and pericyte coverage as well as valve structures in future studies as these are key 
components of mature, functional lymphatic vessels.  
Interstitial flow is an important factor that has been shown to contribute to the 
behavior of cells in the lymphatic vasculature, lymph nodes, and bone marrow18,69,89. 
While flow dynamics and shear stresses have been incorporated in a variety of studies 
using microfluidic devices or other bioreactor platforms, these parameters will likely 
need to be fine-tuned to physiological values to provide the most effective 
microenvironment for immune cell survival and function.  
110 
 
The field of lymphoid tissue engineering has much to contribute to regenerative 
medicine and immunotherapies. As the manufacturing techniques improve and the 
designs home in on the combinations of scaffolds, cells, and signals that are crucial for 
desired functional outcomes, lymphoid tissue models will attain clinical relevance and 
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